var title_f35_28_36288="Retropharyngeal abscess xray";
var content_f35_28_36288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65501&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral soft tissue radiographic demonstration of retropharyngeal abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral radiographs of the neck show: (A) normal lateral cervical view; (B) expansion of the prevertebral soft tissues by a retropharyngeal abscess.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alfred L Weber, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36288=[""].join("\n");
var outline_f35_28_36288=null;
var title_f35_28_36289="Patient information: Sleepwalking in children (The Basics)";
var content_f35_28_36289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/9/17554\">",
"         Patient information: Night terrors, confusional arousals, and nightmares in children (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sleepwalking in children (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H285350432\">",
"      <span class=\"h1\">",
"       What is sleepwalking?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sleepwalking is a condition in which a person walks or talks while he or she is asleep. It happens more often in children than adults.",
"     </p>",
"     <p>",
"      As a parent, it can be scary to see your child sleepwalk. But it&rsquo;s important to know that sleepwalking does not mean that your child is sick or has a medical problem.",
"     </p>",
"     <p>",
"      Most children outgrow their sleepwalking as they get older.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H285350447\">",
"      <span class=\"h1\">",
"       What are the symptoms of sleepwalking?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sleepwalking usually happens in the first part of the night. Sleepwalking children can crawl, walk, run, or talk while asleep. They might try to do something, like start to get dressed or walk out of the house. When children sleepwalk, they can have their eyes open and a blank look on their face. They will not respond to you when you talk to them.",
"     </p>",
"     <p>",
"      An episode of sleepwalking can last a few seconds to minutes, but usually lasts 10 to 20 minutes. After the episode is over, the child will fall back asleep. This might be in his or her own bed or in another place in the house.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H285350462\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. The doctor or nurse should be able to tell if your child is sleepwalking by learning about your child&rsquo;s behavior and doing an exam.",
"     </p>",
"     <p>",
"      Some children might need tests to make sure another condition isn&rsquo;t causing their night-time behavior. Doctors might order tests if children sleepwalk very often or have any of the following symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Loud snoring or gasping for breath during sleep",
"       </li>",
"       <li>",
"        Wetting the bed (if the child used to stay dry at night)",
"       </li>",
"       <li>",
"        Sleepwalking 2 or more times each night",
"       </li>",
"       <li>",
"        Seizures, which are waves of abnormal activity in the brain that can make people pass out or move or behave strangely",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H285350477\">",
"      <span class=\"h1\">",
"       How can I help my child when he or she sleepwalks?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can help your child by making sure he or she doesn&rsquo;t get hurt when sleepwalking. To help keep your child safe, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Keep the windows and doors locked at night so your child can&rsquo;t get outside.",
"       </li>",
"       <li>",
"        Make sure your child does not sleep in a top bunk bed (if he or she sleeps in a bunk bed).",
"       </li>",
"       <li>",
"        Keep sharp, breakable, or dangerous items away from your child&rsquo;s bed or out of the bedroom.",
"       </li>",
"       <li>",
"        Put a safety gate in the doorway of your child&rsquo;s bedroom or at the top of the stairs.",
"       </li>",
"       <li>",
"        Keep the floor clear of clutter or other objects that could make your child trip and fall.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      When your child sleepwalks, there are things you should and should not do. You should NOT try to hold your child down or wake him or her up. Instead, you should gently guide your child back to his or her bed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H285350492\">",
"      <span class=\"h1\">",
"       Will my child need other treatment for sleepwalking?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. If your child doesn&rsquo;t sleepwalk too often and it doesn&rsquo;t cause problems, your child will not need any other treatment. Most children outgrow their sleepwalking as they get older.",
"     </p>",
"     <p>",
"      If the sleepwalking causes problems or your child doesn&rsquo;t outgrow it, talk with the doctor or nurse about treatment. Possible treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines",
"       </li>",
"       <li>",
"        A behavior plan called &ldquo;scheduled awakening&rdquo; &ndash; This involves waking your child every night (for a few moments) at a certain time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H285350507\">",
"      <span class=\"h1\">",
"       Can sleepwalking be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Children are more likely to sleepwalk in certain situations, such as when they do not get enough sleep or have a fever.",
"     </p>",
"     <p>",
"      You might be able to prevent sleepwalking by making sure your child gets enough sleep. To do this, try to stick to a regular sleep schedule. Children younger than 6 years old should get 10 to 12 hours of sleep each night. Older children should get 8 to 10 hours of sleep each night.",
"     </p>",
"     <p>",
"      If your child has trouble falling asleep or getting a good night&rsquo;s sleep, here are some things you can try:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have a set bedtime and bedtime routine for your child.",
"       </li>",
"       <li>",
"        Keep your child&rsquo;s bedtime and wake-up time about the same every day (on school and non-school days).",
"       </li>",
"       <li>",
"        Make the hour before bed a quiet time, and avoid high-energy activities.",
"       </li>",
"       <li>",
"        Keep your child&rsquo;s room quiet and dark. If your child is scared of the dark, use a night light that is not too bright.",
"       </li>",
"       <li>",
"        Don&rsquo;t have a TV in your child&rsquo;s bedroom.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H285350522\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/9/17554?source=see_link\">",
"       Patient information: Night terrors, confusional arousals, and nightmares in children (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/28/36289?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86005 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36289=[""].join("\n");
var outline_f35_28_36289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H285350432\">",
"      What is sleepwalking?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H285350447\">",
"      What are the symptoms of sleepwalking?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H285350462\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H285350477\">",
"      How can I help my child when he or she sleepwalks?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H285350492\">",
"      Will my child need other treatment for sleepwalking?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H285350507\">",
"      Can sleepwalking be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H285350522\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/9/17554?source=related_link\">",
"      Patient information: Night terrors, confusional arousals, and nightmares in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_28_36290="Centruroides exilicauda";
var content_f35_28_36290=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Centruroides exilicauda",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Banner Good Samaritan Medical Center, Department of Medical Toxicology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36290=[""].join("\n");
var outline_f35_28_36290=null;
var title_f35_28_36291="Apraclonidine: Drug information";
var content_f35_28_36291=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Apraclonidine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/15/9460?source=see_link\">",
"    see \"Apraclonidine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Iopidine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F136268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Iopidine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F136303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha",
"      <sub>",
"       2",
"      </sub>",
"      Agonist, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F136270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Postsurgical intraocular pressure elevation (prevention/treatment): Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     0.5%: Instill 1-2 drops in the affected eye(s) 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1%: Instill 1 drop in operative eye 1 hour prior to anterior segment laser surgery, second drop in eye immediately upon completion of procedure",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F136271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F136272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although the topical use of apraclonidine has not been studied in renal failure patients, structurally-related clonidine undergoes a significant increase in half-life in patients with severe renal impairment. Close monitoring of cardiovascular parameters in patients with impaired renal function is advised.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F136273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Close monitoring of cardiovascular parameters in patients with impaired liver function is advised because the systemic dosage form of clonidine is partially metabolized in the liver.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 0.5% (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iopidine&reg;: 0.5% (5 mL, 10 mL); 1% (0.1 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F136255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wait 5 minutes between instillation of other ophthalmic agents to avoid washout of previous dose. After topical instillation, finger pressure should be applied to lacrimal sac to decrease drainage into the nose and throat and minimize possible systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F136254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of postsurgical intraocular pressure (IOP) elevation; short-term, adjunctive therapy in patients who require additional reduction of IOP",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F136309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Iopidine&reg; may be confused with indapamide, iodine, Lodine&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F136301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ocular:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 15%: Discomfort, hyperemia, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 5%: Blanching, blurred vision, conjunctivitis, discharge, dry eye, foreign body sensation, lid edema, tearing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal vision, blepharitis, blepharoconjunctivitis, conjunctival edema, conjunctival follicles, corneal erosion, corneal infiltrate, corneal staining, edema, irritation, keratitis, keratopathy, lid disorder, lid erythema, lid margin crusting, lid retraction, lid scales, pain, photophobia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Other body systems:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Gastrointestinal: Dry mouth (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;3%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, chest pain, facial edema, peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, headache, insomnia, malaise, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Contact dermatitis, dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, taste perversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal coordination, myalgia, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Asthma, dry nose, dyspnea, parosmia, pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Allergic reactions, bradycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F136258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to apraclonidine, clonidine, or any component of the formulation; use with or within 14 days of MAO inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F136242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, coronary insufficiency, or recent myocardial infarction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasovagal reactions: Use with caution in patients with history of vasovagal reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring efficacy: The IOP-lowering efficacy observed during the first month of therapy may not always reflect the long-term level of IOP reduction; routinely monitor IOP.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Embryocidal effects were observed in some animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F136275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F136259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Apraclonidine HCl Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (5 mL): $86.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Iopidine Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (5 mL): $137.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (1): $22.84",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F136251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Closely monitor patients who develop exaggerated reductions in intraocular pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F136261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alfadrops (IN);",
"     </li>",
"     <li>",
"      Iopidine (AR, AT, AU, BE, BF, BG, BJ, BR, CH, CI, CN, DE, DK, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, IE, IL, IT, KE, KP, LR, LU, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, NZ, PE, PL, PT, PY, SC, SD, SE, SG, SL, SN, TN, TR, TZ, UG, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Iopimax (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F136241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apraclonidine is a potent alpha-adrenergic agent similar to clonidine; relatively selective for alpha",
"     <sub>",
"      2",
"     </sub>",
"     -receptors but does retain some binding to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -receptors; appears to result in reduction of aqueous humor formation; its penetration through the blood-brain barrier is more polar than clonidine which reduces its penetration through the blood-brain barrier and suggests that its pharmacological profile is characterized by peripheral rather than central effects.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F136257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Decreased intraocular pressure: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Ocular: Systemically absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, systemic: 8 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8863 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-90976AC03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36291=[""].join("\n");
var outline_f35_28_36291=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136267\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136268\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136303\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136270\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136271\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136272\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136273\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136253\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136238\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136255\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136254\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136309\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136301\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136258\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136242\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298767\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136247\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136249\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136260\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136275\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136259\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136251\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136261\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136241\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136257\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8863\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8863|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?9/15/9460?source=related_link\">",
"      Apraclonidine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_28_36292="Photo well differentiated pancreatic NET";
var content_f35_28_36292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Gross photo of well differentiated pancreatic neuroendocrine tumor shows a well circumscribed mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cut surface is pink tan with scattered yellow areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36292=[""].join("\n");
var outline_f35_28_36292=null;
var title_f35_28_36293="Potassium iodide: Pediatric drug information";
var content_f35_28_36293=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium iodide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"    see \"Potassium iodide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/38/23141?source=see_link\">",
"    see \"Potassium iodide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      iOSAT&trade; [OTC];",
"     </li>",
"     <li>",
"      SSKI&reg;;",
"     </li>",
"     <li>",
"      ThyroSafe&reg; [OTC];",
"     </li>",
"     <li>",
"      Thyroshield&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antithyroid Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Expectorant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of thyroidal uptake of radioactive isotopes of iodine to reduce risk of thyroid cancer following nuclear accident:",
"     </b>",
"     Oral: (Iosat&trade;, ThyroSafe&trade;, ThyroShield&trade;): 16.25 mg once daily;",
"     <b>",
"      Note:",
"     </b>",
"     Continue treatment until the risk of exposure has passed and/or until other measures (evacuation, sheltering, control of the food and milk supply) have been successfully implemented",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Thyroid gland protection during radiopharmaceutical use:",
"     </b>",
"     Oral:  ThyroShield&trade;: 16 mg once on the day before radiopharmaceutical use (Olivier, 2003)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"      see \"Potassium iodide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cutaneous sporotrichosis:",
"     </b>",
"     Limited data available: Children and Adolescents: Oral: SSKI&reg;: Initial: 50 mg (1 drop or 0.05 mL) 3 times daily; increase as tolerated to &le;50 mg/kg/dose (&le;1 drop/kg/dose or &le;0.05 mL/kg/dose) 3 times daily; Maximum: 2500 mg/dose (50 drops/dose or 2.5 mL/dose); continued at the maximum tolerated dosage for several weeks after lesions have resolved (Kauffman, 2007;",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Expectorant:",
"     </b>",
"     Children: Oral: SSKI&reg;: 60-250 mg 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prevention of thyroidal uptake of radioactive isotopes of iodine to reduce risk of thyroid cancer following nuclear accident:",
"     </b>",
"     Oral: Iosat&trade;, ThyroSafe&trade;, ThyroShield&trade;:",
"     <b>",
"      Note:",
"     </b>",
"     Continue treatment until the risk of exposure has passed and/or until other measures (evacuation, sheltering, control of the food and milk supply) have been successfully implemented.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants and Children &le;3 years: 32.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescent &gt;3-18 years and weight  &lt;68 kg (150 lbs): 65 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescent 12-18 years and weight  &ge;68 kg (150 lbs): 130 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Thyroid gland protection during radiopharmaceutical use:",
"     </b>",
"     Limited data available;",
"     <b>",
"      Note:",
"     </b>",
"     Begin at 1-48 hours prior to exposure; continue potassium iodide after radiopharmaceutical administration until risk of exposure has diminished (treatment duration and time of initiation is dependent on the radiopharmaceutical; consult specific protocol; Oral:   Iostat&trade;, ThyroSafe&trade;, ThyroShield&trade; (Giammarile, 2008; Olivier, 2003):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &lt;5 kg: 16 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &gt;5 kg:  32 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     1-3 years and 5-15 kg: 32 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;3-12 years and 15-50 kg: 65 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;50 kg: 130 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;50 kg: 65 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;50 kg: 130 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Thyroidectomy, preoperative preparation:",
"     </b>",
"     Children and Adolescents: Oral: SSKI&reg;: 150-350 mg (3-7 drops or 0.15-0.35 mL) 3 times daily; administer for 10 days before surgery; if not euthyroid prior to surgery, consider concurrent beta-blockade (eg, propranolol) in the immediate preoperative period to reduce the risk of thyroid storm (Bahn, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Thyrotoxic crisis/thyroid storm:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Administer at least 1 hour after antithyroid drug (eg, methimazole) administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants: Oral: SSKI&reg;: 100 mg (2 drops or 0.1 mL) 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents: Oral: SSKI&reg;: 250 mg (5 drops or 0.25 mL)  2-4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Expectorant:",
"     </b>",
"     Oral: SSKI&reg;: 300-600 mg 3-4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Preparation for thyroidectomy:",
"     </b>",
"     Oral: 50-100 mg (1-2 drops",
"     <b>",
"      or",
"     </b>",
"     0.05-0.1 mL SSKI&reg;) 3 times daily; administer for 10 days before surgery; if not euthyroid prior to surgery, consider concurrent beta-blockade (eg, propranolol) in the immediate preoperative period to reduce the risk of thyroid storm (Bahn, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Sporotrichosis (cutaneous, lymphocutaneous):",
"     </b>",
"     Oral: SSKI&reg;: Initial: 5 drops 3 times daily; increase to 40-50 drops 3 times daily as tolerated until 2-4 weeks after lesions have resolved (usual duration: 3-6 months) (Kauffman, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Thyroid gland protection during radiopharmaceutical use:",
"     </b>",
"     Oral: Tablet: 130 mg once daily or Solution (SSKI&reg;): 4 drops 3 times daily.",
"     <b>",
"      Note:",
"     </b>",
"     Begin at 1-48 hours prior to exposure. Continue potassium iodide after radiopharmaceutical administration until risk of exposure has diminished (treatment duration and time of initiation is dependent on the radiopharmaceutical, consult specific protocol).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Thyrotoxic crisis/thyroid storm:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Administer at least 1-2 hours after antithyroid drug administration: 250 mg (5 drops",
"     <b>",
"      or",
"     </b>",
"     0.25 mL SSKI&reg;) every 6 hours (Bahn, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      To reduce risk of thyroid cancer following nuclear accident (Iosat&trade;, ThyroSafe&trade;, ThyroShield&trade;):",
"     </b>",
"     Oral: Adults (including pregnant/lactating women): Oral: 130 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Dosing should continue until risk of exposure has passed or other measures have are implemented.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SSKI&reg;: 1 g/mL (30 mL, 237 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thyroshield&reg;: 65 mg/mL (30 mL) [contains propylene glycol; black raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     iOSAT&trade;: 130 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ThyroSafe&reg;: 65 mg [scored; equivalent to iodine 50 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13755335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer after meals with food or milk or dilute with a large quantity of water, fruit juice, milk, or broth",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1061265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light; keep container tightly closed. SSKI&reg; if exposed to cold temperatures may develop crystallization; warming with shaking will redissolve crystals; if solution becomes brown/yellow in color, it should be discarded.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Expectorant for the symptomatic treatment of chronic pulmonary diseases complicated by mucous (SSKI&reg;: FDA approved in adults); block thyroidal uptake of radioactive isotopes of iodine in a radiation emergency or other exposure to radioactive iodine (Iosat&trade;, ThyroSafe&trade;, ThyroShield&trade;: FDA approved in all ages); has also been used to reduce thyroid vascularity prior to thyroidectomy and management of thyrotoxic crisis; lymphocutaneous and cutaneous sporotrichosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F802361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Potassium iodide products, including saturated solution of potassium iodide (SSKI&reg;) may be confused with potassium iodide and iodine (Strong Iodide Solution or Lugol's solution)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F212019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrhythmia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, fatigue, fever, numbness, tingling sensation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Skin rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Goiter, hyperthyroidism (prolonged use), hypothyroidism (prolonged use), myxedema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, enlargement of salivary glands, gastric distress, gastrointestinal hemorrhage, metallic taste, nausea, stomach pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic &amp; oncologic: Lymphedema, thyroid adenoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypersensitivity: Hypersensitivity reaction (angioedema, cutaneous and mucosal hemorrhage, serum sickness-like symptoms)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Musculoskeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Iodine poisoning (with prolonged treatment/high doses)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iodides or any component; dermatitis herpetiformis, hypocomplementemic vasculitis, nodular thyroid condition with heart disease",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cystic fibrosis; may have exaggerated susceptibility to goitrogenic effects; use caution in patients with myotonia congenita, a history of thyroid disease, cardiac disease, renal impairment, Addison's disease, tuberculosis, or acute bronchitis. Treatment with potassium iodide may cause flare-up of acne and/or dermatitis. Use with caution in patients receiving medications that increase serum potassium concentrations. With radiopharmaceutical use, potassium iodide must be administered prior to receiving radiopharmaceuticals that require thyroid protection.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use can lead to hypothyroidism.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Potassium Iodide may enhance the hypothyroid effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F211973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iodide crosses the placenta (may cause hypothyroidism and goiter in fetus/newborn). Use as an expectorant during pregnancy is contraindicated by the AAP. Use for protection against thyroid cancer secondary to radioactive iodine exposure is considered acceptable based upon risk:benefit, keeping in mind the dose and duration. Repeat dosing should be avoided if possible. Refer to Iodine for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thyroid function tests; sign/symptoms of hyperthyroidism; thyroid function should be monitored in pregnant women, neonates, and young infants if repeat doses are required following radioactive iodine exposure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduces viscosity of mucus by increasing respiratory tract secretions; inhibits the release of thyroid hormone; following radioactive iodine exposure, potassium iodide blocks the uptake of radioiodine by the thyroid, reducing the risk of thyroid cancer",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antithyroid effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 10-15 days after continuous therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: May persist up to 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Radioactive iodine exposure:",
"     </b>",
"     Duration: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1061276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SSKI&reg; 10 drops = potassium iodide 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F211967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     A 16.25 mg/5 mL oral solution may be made with tablets. Crush one 130 mg tablet and reduce to a fine powder. Add 20 mL of water and mix until powder is dissolved. Add an additional 20 mL of low-fat milk (white or chocolate), orange juice, flat soda, raspberry syrup, or infant formula. Stable for 7 days under refrigeration.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     To prepare an 8.125 mg/5 mL oral solution, crush one 65 mg tablet and reduce to a fine powder. Add 20 mL of water and mix until powder is dissolved. Add an additional 20 mL of low-fat milk (white or chocolate), orange juice, flat soda, raspberry syrup, or infant formula. Stable for 7 days under refrigeration.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Environmental Health. Radiation Disasters and Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 111(6 Pt 1):1455-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/28/36293/abstract-text/12777572 /pubmed\" id=\"12777572 \" target=\"_blank\">",
"        12777572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bahn RS (Chair), Burch HB, Cooper DS, et al, \"Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,\"",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2011, 21(6):593-646.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/28/36293/abstract-text/21510801/pubmed\" id=\"21510801\" target=\"_blank\">",
"        21510801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giammarile F, Chiti A, Lassmann M,et al, \"EANM Procedure Guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) Therapy,\"",
"      <i>",
"       Eur J Nucl Med Mol Imaging",
"      </i>",
"      , 2008, 35(5):1039-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/28/36293/abstract-text/18274745/pubmed\" id=\"18274745\" target=\"_blank\">",
"        18274745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kauffman CA, Bustamante B, Chapman SW, et al, \"Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(10):1255-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/28/36293/abstract-text/17968818/pubmed\" id=\"17968818\" target=\"_blank\">",
"        17968818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nayak B and Burman K, \"Thyrotoxicosis and Thyroid Storm,\"",
"      <i>",
"       Endocrinol Metab Clin North Am",
"      </i>",
"      , 2006, 35(4):663-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/28/36293/abstract-text/17127140/pubmed\" id=\"17127140\" target=\"_blank\">",
"        17127140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olivier P, Colarinha P, Fettich J, et al, \"Guidelines for Radioiodinated MIBG Scintigraphy in Children,\"",
"      <i>",
"       Eur J Nucl Med Mol Imaging",
"      </i>",
"      , 2003, 30(5):45-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/28/36293/abstract-text/12658506/pubmed\" id=\"12658506\" target=\"_blank\">",
"        12658506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Potassium Iodide as a Thyroid Blocking Agent in a Radiation Emergency: Final Recommendations on Use,&rdquo; Washington DC, Bureau of Radiological Health and Bureau of Drugs, Food and Drug Administration, 1982.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Sporotrichosis,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 598-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Food and Drug Administration, &ldquo;FDA's Guidance on Protection of Children and Adults Against Thyroid Cancer in Case of Nuclear Accident,&rdquo; FDA Talk Paper. Available at: file://www.fda.gov/bbs/topics/answers/2001/ans01126.html. Accessed January 11, 2002.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12718 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36293=[""].join("\n");
var outline_f35_28_36293=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211985\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061268\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444786\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061262\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211963\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13755335\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061271\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061265\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061270\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F802361\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212019\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061275\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061261\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061260\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299922\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211956\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211959\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211973\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061267\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061259\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061274\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061276\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211967\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12718\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12718|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=related_link\">",
"      Potassium iodide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/38/23141?source=related_link\">",
"      Potassium iodide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_28_36294="Clinical aspects of serum bilirubin determination";
var content_f35_28_36294=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical aspects of serum bilirubin determination",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/28/36294/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/28/36294/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/28/36294/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/28/36294/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/28/36294/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/28/36294/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/28/36294/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of blood tests are available that reflect the condition of the liver. The most common tests used in clinical practice include the serum aminotransferases, bilirubin, alkaline phosphatase, albumin, and prothrombin time. These tests are often referred to as \"liver function tests\", although this term is somewhat misleading since most do not accurately reflect how well the liver is functioning, and abnormal values can be caused by diseases unrelated to the liver. In addition, these tests may be normal in patients who have advanced liver disease.",
"   </p>",
"   <p>",
"    Several specialized tests have also been developed (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/44/32450?source=see_link\">",
"     indocyanine green",
"    </a>",
"    clearance), which, although uncommonly used in clinical practice, can measure specific aspects of hepatic function.",
"   </p>",
"   <p>",
"    Despite their limitations, liver biochemical and function tests have many applications in clinical medicine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They provide a noninvasive method to screen for the presence of liver disease. The serum aminotransferases, for example, are part of panel of tests used to screen all blood donors in the United States for the presence of transmissible viruses.",
"     </li>",
"     <li>",
"      They can be used to measure the efficacy of treatments for liver disease (such as immunosuppressant agents for autoimmune hepatitis). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=see_link\">",
"       \"Treatment of autoimmune hepatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They can be used to monitor the progression of a disease such as viral or alcoholic hepatitis.",
"     </li>",
"     <li>",
"      They can reflect the severity of liver disease, particularly in patients who have cirrhosis. As an example, the Child-Turcotte-Pugh score, which incorporates the prothrombin time and serum bilirubin and albumin concentrations, can predict survival (",
"      <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pattern of abnormalities on these tests is more accurate than any of the individual tests. Elevation of serum aminotransferases indicates hepatocellular injury, while elevation of the alkaline phosphatase indicates cholestasis. Recognition of patterns that are consistent with specific diseases can prompt appropriate additional testing.",
"   </p>",
"   <p>",
"    The liver biochemical and function tests that are used commonly in clinical practice and that are used occasionally for specific circumstances can be categorized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tests that detect injury to hepatocytes &ndash; Most of these tests measure the activity of hepatic enzymes, such as the aminotransferases, in the circulation. These enzymes are normally intracellular, but are released when hepatocytes are injured. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/63/21494?source=see_link\">",
"       \"Liver biochemical tests that detect injury to hepatocytes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tests of the liver's capacity to transport organic anions and metabolize drugs &ndash; These tests measure the liver's ability to clear endogenous or exogenous substances from the circulation. The best studied include serum measurements of bilirubin, bile acids, caffeine, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      metabolites, a variety of breath tests, and clearance tests such as bromsulphalein (BSP) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/44/32450?source=see_link\">",
"       indocyanine green",
"      </a>",
"      (ICG).",
"     </li>",
"     <li>",
"      Tests of the liver's biosynthetic capacity &ndash; The most commonly performed tests to assess the biosynthetic capacity of the liver are the serum albumin and the prothrombin time (which requires the presence of clotting factors produced in the liver). Other tests that have been used are the serum concentrations of lipoproteins, ceruloplasmin, ferritin, and alpha 1-antitrypsin.",
"     </li>",
"     <li>",
"      Tests that detect chronic inflammation in the liver, altered immunoregulation, or viral hepatitis &ndash; These tests include the immunoglobulins, hepatitis serologies, and specific autoantibodies. Most of these substances are proteins made by B lymphocytes, not by hepatocytes. However, some are quite specific for certain liver diseases, such as antimitochondrial antibodies in primary biliary cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41641?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will highlight practical considerations in serum bilirubin measurement. The approach to a patient who has hyperbilirubinemia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .) Additional tests of the liver's capacity to transport organic anions and metabolize drugs as well as other categories of liver function tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/22/22889?source=see_link\">",
"     \"Tests of the liver's capacity to transport organic anions and metabolize drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BILIRUBIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilirubin is the catabolic product of heme metabolism, which is formed by the breakdown of heme present in hemoglobin, myoglobin, cytochromes, catalase, peroxidase, and tryptophan pyrrolase (",
"    <a class=\"graphic graphic_figure graphicRef65197 \" href=\"mobipreview.htm?12/7/12415\">",
"     figure 1",
"    </a>",
"    ). Eighty percent of the daily bilirubin production (250 to 400 mg) is derived from hemoglobin; the remaining 20 percent is contributed by other heme proteins and a rapidly turning-over small pool of free heme. Some of the bilirubin produced is then conjugated in the liver (",
"    <a class=\"graphic graphic_figure graphicRef52393 \" href=\"mobipreview.htm?30/51/31536\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27943?source=see_link\">",
"     \"Bilirubin metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Measurement of serum bilirubin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several laboratory techniques have been developed for measuring the serum bilirubin concentration. The specific technique used has implications for the interpretation of serum values.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     van den Bergh method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms \"direct-\" and \"indirect-reacting\" bilirubin were based upon laboratory techniques developed at the beginning of the 20th century that are still used in some clinical laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/1\">",
"     1",
"    </a>",
"    ]. Direct and indirect bilirubin reflect the concentrations of conjugated and unconjugated bilirubin, respectively.",
"   </p>",
"   <p>",
"    The technique involves the reaction of bilirubin with a diazo compound (diazotized sulfanilic acid), which creates two relatively stable dipyrryl azopigments. These fractions can be detected spectrophotometrically (their maximal absorption occurs at 540 nm). The indirect and direct fractions can be distinguished based upon their rate of production in the absence or presence of alcohol. The fraction produced within one minute in the absence of alcohol represents the concentration of direct bilirubin; the total serum bilirubin is that amount that reacts in 30 minutes after the addition of alcohol; and the indirect fraction is the difference between the total and the direct bilirubin. The fast reaction of direct (conjugated bilirubin) is due to the absence of internal hydrogen bonding and the fact that it is water soluble.",
"   </p>",
"   <p>",
"    Total serum bilirubin concentrations using this technique are between 0.2 and 0.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2 to 15.4",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in 95 percent of the general population, and below 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (18",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in 99 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Direct bilirubin represents up to 30 percent, or 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.1",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    of the total bilirubin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advances in laboratory methodology have demonstrated that the diazo method may not accurately reflect the concentration of conjugated and unconjugated bilirubin. Direct bilirubin slightly overestimates the conjugated bilirubin concentration because a fraction of unconjugated bilirubin (about 10 to 15 percent) also gives a direct reaction using the van den Bergh method. There are several other potential sources of error. Endogenous substances, such as plasma lipids, and drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , interfere with the diazo reaction, and can produce unreliable results. Fortunately, these interactions are only significant when the bilirubin concentration is normal or slightly elevated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Bilirubin complexed to albumin (delta bilirubin) also may give a direct reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Delta bilirubin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Alkaline methanolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more accurate and sensitive quantification of bilirubin requires chromatographic analysis, such as high-performance liquid chromatography (HPLC) and reflectance fluorometry. One such method involves alkaline methanolysis of bilirubin followed by chloroform extraction of the bilirubin methyl esters. Separation of these esters is performed using HPLC and spectrophotometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other HPLC-based methods are also available that do not require alkaline methanolysis, although globulins and other high-molecular weight proteins must be precipitated from serum before chromatography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Dry reagent chemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other methods that use dry reagent chemistry have been reported. One method, which is used in many clinical chemistry laboratories, is based upon photographic film technology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/8\">",
"     8",
"    </a>",
"    ]. It can be automated and appears able to measure conjugated and unconjugated bilirubin accurately. This technique also has the advantage of being able to detect delta bilirubin, the fraction conjugated to albumin.",
"   </p>",
"   <p>",
"    These newer techniques have added considerably to our understanding of bilirubin metabolism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Virtually 100 percent of the serum bilirubin in healthy people, including those with Gilbert's syndrome, is unconjugated. Conjugated hyperbilirubinemia occurs only in hepatobiliary diseases.",
"     </li>",
"     <li>",
"      The observation that jaundiced patients with hepatobiliary diseases have lower serum bilirubin concentrations measured by non-diazo- than diazo-based methods suggests that there are additional diazo-positive compounds distinct from bilirubin in their circulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Monoglucuronides of bilirubin predominate over the diglucuronides in jaundiced patients with hepatobiliary disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Delta bilirubin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to detect delta bilirubin has important clinical implications. This albumin-linked bilirubin fraction is formed in the serum when hepatic excretion of bilirubin glucuronides is impaired; as a result, it represents a significant fraction of total serum bilirubin in patients with cholestasis and hepatobiliary disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/7\">",
"     7",
"    </a>",
"    ]. In one series, for example, delta bilirubin constituted 8 to 90 percent of total bilirubin in patients with hepatocellular and cholestatic jaundice, but was undetectable in normal volunteers, neonates with physiologic jaundice, or those with Gilbert's disease or hemolysis. Because of its covalent binding to albumin, the clearance of delta bilirubin is approximately the same as albumin rather than the short half-life of conjugated bilirubin that is not albumin bound (12 to 24 days versus 4 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appreciation of the prolonged half-life of delta bilirubin has explained two observations in jaundiced patients that were previously not understood:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because conjugated bilirubin is excreted in the urine, patients with conjugated hyperbilirubinemia develop bilirubinuria. However, some patients with conjugated hyperbilirubinemia do not exhibit bilirubinuria during the recovery phase of their disease because delta bilirubin persists longer than bilirubin and delta bilirubin is not excreted in the urine.",
"     </li>",
"     <li>",
"      Late in the recovery phase of hepatobiliary disorders, virtually all the conjugated bilirubin may be in the albumin-linked form. As a result, elevated serum bilirubin levels decline more slowly than expected in some patients who otherwise appear to be recovering satisfactorily.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE OF SERUM BILIRUBIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bilirubin normally present in serum reflects a balance between production and clearance. Thus, elevated serum bilirubin concentrations can be due to three causes which can sometimes coexist:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overproduction of bilirubin",
"     </li>",
"     <li>",
"      Impaired uptake, conjugation, or excretion of bilirubin",
"     </li>",
"     <li>",
"      Backward leakage from damaged hepatocytes or bile ducts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An approach to patients who present with hyperbilirubinemia is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .) This section will review the clinical significance of hyperbilirubinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Indication of the severity of hepatic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total serum bilirubin is",
"    <strong>",
"     not",
"    </strong>",
"    a sensitive indicator of hepatic dysfunction. Concentrations of serum bilirubin may be normal despite moderate to severe hepatic parenchymal injury or a partially or transiently obstructed bile duct.",
"   </p>",
"   <p>",
"    This lack of sensitivity can be explained in part by the reserve capacity of the human liver to remove bilirubin. Studies of healthy people who were given infusions of unconjugated bilirubin, and observations in patients who have hemolysis, have demonstrated that the normal liver can remove at least twice the normal daily bilirubin load without the development of hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/11\">",
"     11",
"    </a>",
"    ]. The reserve capacity may be even higher based upon the maximal rate of excretion of bilirubin in bile. The maximal daily excretion of bilirubin is approximately 55.2",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    which is more than 10 times greater than the average daily production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Correlation of bilirubin concentration with jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a steady state, the serum bilirubin concentration usually reflects the intensity of jaundice and the amount of bilirubin pigment in the body. However, several factors can influence the relationship between serum bilirubin and the total body bilirubin content. The serum bilirubin concentration may be lowered transiently by salicylates, sulfonamides, or free fatty acids, which displace bilirubin from its attachment to plasma albumin, thereby enhancing transfer of the pigment into tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, an increase in the serum albumin concentration (eg, due to volume contraction) may induce a temporary shift of bilirubin from tissue sites into the circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Significance of the serum bilirubin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum total bilirubin concentration is seldom of value in specifying the cause of jaundice in individual patients because values among the various causes of jaundice overlap considerably [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/15\">",
"     15",
"    </a>",
"    ]. As general rules:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uncomplicated hemolysis seldom causes a serum bilirubin value in excess of 5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (85.5",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Parenchymal liver disease and incomplete extrahepatic biliary obstruction due to calculi are associated with lower serum bilirubin concentrations than malignant obstruction of the bile duct.",
"     </li>",
"     <li>",
"      Although few controlled studies have evaluated the usefulness of the level and duration of the serum bilirubin for determining disease prognosis, several general relationships appear to apply. The higher the serum bilirubin concentration in viral hepatitis, the greater the histologic evidence of hepatocellular damage and the longer the course of the disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/17\">",
"       17",
"      </a>",
"      ]. Similarly a serum bilirubin concentration higher than 5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (85.5",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      is associated with a poor prognosis in alcoholic hepatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. A rising bilirubin concentration suggests a poor prognosis in patients with primary biliary cirrhosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the correlation of serum bilirubin concentration with disease outcome does not always hold true. As an example, patients may die of fulminant hepatitis with only modest elevations of the serum bilirubin. Furthermore, conditions associated with excess bilirubin production (such as hemolysis) or decreased clearance (such as renal insufficiency) can result in hyperbilirubinemia out of proportion to the degree of hepatic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Value of fractionating the bilirubin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated levels of unconjugated bilirubin usually result from overproduction or impaired uptake or conjugation of bilirubin. In contrast, conjugated hyperbilirubinemia is more commonly due to decreased excretion or backward leakage (as from an obstructed biliary system), and is usually a more sensitive indicator of hepatic dysfunction. The new, more precise methods for measuring serum bilirubin (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Measurement of serum bilirubin'",
"    </a>",
"    above) have demonstrated that virtually 100 percent of the serum bilirubin in healthy people and those with Gilbert's syndrome is unconjugated. Measurable amounts of conjugated bilirubin in serum using the most specific laboratory techniques are found only in hepatobiliary disease. However, many clinical laboratories continue to use less precise techniques, and thus report a normal range for conjugated bilirubin.",
"   </p>",
"   <p>",
"    The major value of fractionating total serum bilirubin is for the detection of states characterized by unconjugated hyperbilirubinemia (",
"    <a class=\"graphic graphic_table graphicRef55607 \" href=\"mobipreview.htm?27/55/28541\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7065?source=see_link\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .) These diagnoses should be considered when the serum indirect bilirubin concentration is greater than 1.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (20.5",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and the direct fraction constitutes less than 20 percent of the total serum bilirubin. Using the diazo method (see",
"    <a class=\"local\" href=\"#H4\">",
"     'van den Bergh method'",
"    </a>",
"    above), an increase in the direct bilirubin concentration above 0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.1",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or, using the more accurate techniques, a direct bilirubin concentration above 0.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.7",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    should raise suspicion for liver injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fractionation of the serum bilirubin concentration in jaundiced patients does not permit accurate distinction between parenchymal (hepatocellular) and cholestatic (obstructive) jaundice. The accurate HPLC methods for measuring serum bilirubin demonstrate that unconjugated and conjugated bilirubin are both increased in hepatobiliary disease without a consistent difference in pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/5\">",
"     5",
"    </a>",
"    ]. Levels of both bilirubin monoglucuronide and diglucuronide are elevated, with the monoglucuronides predominating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Urine bilirubin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of bilirubin in the urine reflects direct hyperbilirubinemia and therefore underlying hepatobiliary disease. In contrast to conjugated bilirubin, unconjugated bilirubin is tightly bound to albumin; as a result, it is not filtered by the glomerulus or present in the urine.",
"   </p>",
"   <p>",
"    Conjugated bilirubin may be found in the urine when the total serum bilirubin concentration is normal because the renal reabsorptive capacity for conjugated bilirubin is low and the methods used can detect urinary bilirubin concentrations as low as 0.05",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.9",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/21\">",
"     21",
"    </a>",
"    ]. Thus, bilirubinuria may be an early sign of liver disease, while the clearance of bilirubin from the urine may be an early sign of recovery, since, as noted above, delta bilirubin is protein-bound (thereby increasing its half life compared with nonbound conjugated bilirubin and preventing its filtration across the glomerulus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36294/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4193547\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilirubin is the catabolic product of heme metabolism, which is formed by the breakdown of heme present in hemoglobin, myoglobin, cytochromes, catalase, peroxidase, and tryptophan pyrrolase (",
"      <a class=\"graphic graphic_figure graphicRef65197 \" href=\"mobipreview.htm?12/7/12415\">",
"       figure 1",
"      </a>",
"      ). Eighty percent of the daily bilirubin production (250 to 400 mg) is derived from hemoglobin; the remaining 20 percent is contributed by other heme proteins and a rapidly turning-over small pool of free heme. Some of the bilirubin produced is then conjugated in the liver (",
"      <a class=\"graphic graphic_figure graphicRef52393 \" href=\"mobipreview.htm?30/51/31536\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The bilirubin normally present in serum reflects a balance between production and clearance. Thus, elevated serum bilirubin concentrations can be due to three causes that sometimes coexist (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical significance of serum bilirubin'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Overproduction of bilirubin",
"     </li>",
"     <li>",
"      Impaired uptake, conjugation, or excretion of bilirubin",
"     </li>",
"     <li>",
"      Backward leakage from damaged hepatocytes or bile ducts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total serum bilirubin is",
"      <strong>",
"       not",
"      </strong>",
"      a sensitive indicator of hepatic dysfunction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Indication of the severity of hepatic dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The level of the total serum bilirubin is seldom of value in specifying the cause of jaundice in individual patients because values among the various causes of jaundice overlap considerably. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Significance of the serum bilirubin concentration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24416393\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/1\">",
"      ZIEVE L, HILL E, HANSON M, et al. Normal and abnormal variations and clinical significance of the one-minute and total serum bilirubin determinations. J Lab Clin Med 1951; 38:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/2\">",
"      Werner M, Tolls RE, Hultin JV, Mellecker J. Influence of sex and age on the normal range of eleven serum constituents. Z Klin Chem Klin Biochem 1970; 8:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/3\">",
"      TISDALE WA, KLATSKIN G, KINSELLA ED. The significance of the direct-reacting fraction of serum bilirubin in hemolytic jaundice. Am J Med 1959; 26:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/4\">",
"      Blanckaert N. Analysis of bilirubin and bilirubin mono- and di-conjugates. Determination of their relative amounts in biological samples. Biochem J 1980; 185:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/5\">",
"      Blanckaert N, Kabra PM, Farina FA, et al. Measurement of bilirubin and its monoconjugates and diconjugates in human serum by alkaline methanolysis and high-performance liquid chromatography. J Lab Clin Med 1980; 96:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/6\">",
"      Blanckaert N, Servaes R, Leroy P. Measurement of bilirubin-protein conjugates in serum and application to human and rat sera. J Lab Clin Med 1986; 108:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/7\">",
"      Weiss JS, Gautam A, Lauff JJ, et al. The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med 1983; 309:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/8\">",
"      Defreese JD, Wang TS. Properties and determination of serum and bilirubin. Crit Rev Clin Lab Sci 1984; 19:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/9\">",
"      Lauff JJ, Kasper ME, Ambrose RT. Quantitative liquid-chromatographic estimation of bilirubin species in pathological serum. Clin Chem 1983; 29:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/10\">",
"      Bloomer JR, Berk PD, Howe RB, Berlin NI. Interpretation of plasma bilirubin levels based on studies with radioactive bilirubin. JAMA 1971; 218:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/11\">",
"      Thompson HE, Wyatt BL. Experimentally induced jaundice (hyperbilirubinemia): Report of animal experimentation and of physiologic effect of jaundice in patients with atrophic arthritis. Arch Intern Med 1938; 61:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/12\">",
"      Raymond GD, Galambos JT. Hepatic storage and excretion of bilirubin in man. Am J Gastroenterol 1971; 55:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/13\">",
"      Schmid R, Diamond I, Hammaker L, Gundersen CB. Interaction of bilirubin with albumin. Nature 1965; 206:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/14\">",
"      Diamond I, Schmid R. Experimental bilirubin encephalopathy. The mode of entry of bilirubin-14C into the central nervous system. J Clin Invest 1966; 45:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/15\">",
"      HOFFBAUER FW, RAMES ED, MEINERT JK. Limitations and merits of a single serum sample analysis in the differential diagnosis of jaundice. J Lab Clin Med 1949; 34:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/16\">",
"      KLATSKIN G. Bile pigment metabolism. Annu Rev Med 1961; 12:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/17\">",
"      SHERLOCK SP. Biochemical investigations in liver disease; some correlations with hepatic histology. J Pathol Bacteriol 1946; 58:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/18\">",
"      Hardison WG, Lee FI. Prognosis in acute liver disease of the alcoholic patient. N Engl J Med 1966; 275:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/19\">",
"      Harinasuta U, Chomet B, Ishak K, Zimmerman HJ. Steatonecrosis--Mallory body type. Medicine (Baltimore) 1967; 46:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/20\">",
"      Kim WR, Wiesner RH, Therneau TM, et al. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology 1998; 28:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36294/abstract/21\">",
"      KLATSKIN G, BUNGARDS L. An improved test for bilirubin in urine. N Engl J Med 1953; 248:712.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3567 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36294=[""].join("\n");
var outline_f35_28_36294=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4193547\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BILIRUBIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Measurement of serum bilirubin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - van den Bergh method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Alkaline methanolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Dry reagent chemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Delta bilirubin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL SIGNIFICANCE OF SERUM BILIRUBIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Indication of the severity of hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Correlation of bilirubin concentration with jaundice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Significance of the serum bilirubin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Value of fractionating the bilirubin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Urine bilirubin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4193547\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24416393\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3567\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3567|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/7/12415\" title=\"figure 1\">",
"      Bilirubin synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/51/31536\" title=\"figure 2\">",
"      Bilirubin in hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3567|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/21/8540\" title=\"table 1\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/55/28541\" title=\"table 2\">",
"      Classification of jaundice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27943?source=related_link\">",
"      Bilirubin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7065?source=related_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/63/21494?source=related_link\">",
"      Liver biochemical tests that detect injury to hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/22/22889?source=related_link\">",
"      Tests of the liver's capacity to transport organic anions and metabolize drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_28_36295="Neuroendocrine carcinoma stain";
var content_f35_28_36295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large cell neuroendocrine carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Synaptophysin immuno-peroxidase stain showing diffuse reactivity confirming that this tumor has neuroendocrine differentiation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36295=[""].join("\n");
var outline_f35_28_36295=null;
var title_f35_28_36296="Allogeneic hematopoietic cell transplantation in multiple myeloma";
var content_f35_28_36296=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Allogeneic hematopoietic cell transplantation in multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/28/36296/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/28/36296/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/28/36296/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/28/36296/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/28/36296/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/28/36296/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/28/36296/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) may be the only treatment for patients with multiple myeloma that has a chance of producing cure. Its use, however, is limited since even ideal candidates who undergo allogeneic HCT have a high rate of treatment-related mortality, and because its efficacy compared with autologous HCT is not fully established. The treatment-related mortality associated with allogeneic HCT is decreasing with the advent of nonmyeloablative preparative regimens. At the same time, new chemotherapeutic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ) are being incorporated into the initial treatment of multiple myeloma, and survival with chemotherapy alone or with autologous HCT is improving. As such, the role of allogeneic HCT in the treatment of multiple myeloma is not clear.",
"   </p>",
"   <p>",
"    The use of allogeneic HCT in the management of patients with multiple myeloma will be reviewed here. The process of determining the appropriate initial therapy for patients with multiple myeloma, eligibility guidelines for HCT, and response criteria used to evaluate the treatment of multiple myeloma are discussed separately, as is a comparison of allogeneic HCT to autologous HCT and chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31526?source=see_link\">",
"     \"Evaluating response to treatment of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"hematopoietic cell transplantation\" (HCT) will be used throughout this review as a general term to cover transplantation of progenitor (stem) cells from any source (eg, bone marrow, peripheral blood, cord blood). Otherwise, the source of such cells will be specified (eg, autologous peripheral blood progenitor cell transplantation). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link\">",
"     \"Sources of hematopoietic stem cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MYELOABLATIVE HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloablative allogeneic HCT requires hematopoietic cells from an HLA-matched donor, which are given after the patient receives high dose chemotherapy and total body radiation. Allogeneic HCT has two advantages over autologous HCT: the graft does not contain tumor cells; and the transplant can produce a graft-versus-myeloma effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Less than 5 to 10 percent of patients with multiple myeloma are candidates for this approach due to its high toxicity. A detailed discussion on eligibility guidelines is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link&amp;anchor=H11#H11\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Allogeneic HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allogeneic HCT for myeloma is associated with an early mortality of at least 20 percent and an overall mortality of 30 to 50 percent, due to fungal infections, interstitial pneumonitis, and graft-versus-host disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. This mortality rate limits the use of myeloablative allogeneic HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/9\">",
"     9",
"    </a>",
"    ]. Accordingly, myeloablative HCT is seldom used in the treatment of myeloma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link&amp;anchor=H15#H15\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Autologous versus allogeneic HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The outcome after allogeneic HCT is best in patients with a low initial tumor burden who go into complete remission after first-line chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/3\">",
"     3",
"    </a>",
"    ]. However, myeloma usually relapses after allogeneic HCT, even in complete responders. In a series of 80 patients in Seattle who underwent allogeneic HCT, only 5 were alive without evidence of disease 4 to 7 years after HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the majority of these patients had chemotherapy-resistant disease, which may have contributed to the relatively poor long-term outcome.",
"   </p>",
"   <p>",
"    At this time, standard myeloablative transplants are rarely performed in myeloma, and are not recommended outside of a clinical trial setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/10\">",
"     10",
"    </a>",
"    ]. However, myeloablative allogeneic transplantation is considered occasionally in selected patients (age less than 60 years) with high risk myeloma who have a fully-matched donor and are willing to accept a high early treatment-related mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SYNGENEIC HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a limited number of syngeneic (ie, identical twin donor) transplants have been performed in multiple myeloma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The European Group for Blood and Marrow Transplantation performed a case-matched analysis on 25 syngeneic transplants (24 using bone marrow and one using peripheral blood stem cells) and compared the results with 125 patients who underwent autologous transplantation and another 125 who underwent allogeneic transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/11\">",
"       11",
"      </a>",
"      ]. Only two twins died of transplant-related toxicity. Overall survival for the twins was 73 months, significantly better than that of the case-matched autologous transplants (44 months); both groups outperformed the allogeneic transplants.",
"     </li>",
"     <li>",
"      The Seattle Marrow Transplant Team performed syngeneic transplants on five patients with multiple myeloma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/12\">",
"       12",
"      </a>",
"      ]. Four patients responded to therapy, while one patient died one month after transplant from cytomegalovirus-associated interstitial pneumonitis. Response durations for these four patients were 6, 17, 18, and more than 72 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These reports support the use of syngeneic HCT in place of an autologous HCT if a twin donor is available. If an identical twin donor is available, it is reasonable to consider a syngeneic HCT in place of autologous HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     T CELL DEPLETED ALLOGENEIC HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of T cell-depleted peripheral blood stem cells decreases the incidence of graft-versus-host disease (GVHD) and reduces transplant mortality, issues which are especially important in patients with multiple myeloma. However, in some of the available studies, treatment-related mortality has been appreciable, while in others relapse may be more frequent, due in part to lessening of graft-versus-myeloma effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/1,13\">",
"     1,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a study of 53 patients with previously untreated multiple myeloma and an HLA-identical sibling received induction therapy followed by a partially T cell-depleted myeloablative allogeneic HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/14\">",
"     14",
"    </a>",
"    ]. Although the overall response rate was 89 percent, treatment-related mortality was 34 percent and 26 percent of patients died from progressive myeloma. At a median follow-up of 38 months, only 3 of the 20 surviving patients were in long-term complete remission.",
"   </p>",
"   <p>",
"    The use of a T cell depleted allogeneic HCT, combined with late donor lymphocyte infusion (DLI) to increase the graft-versus-myeloma effect is an approach currently under investigation. In one study, treatment-related toxicity was appreciable; only 14 of the 24 patients were able to receive a T cell depleted HCT plus DLI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/15\">",
"     15",
"    </a>",
"    ]. However, patients completing the full program had an estimated two-year progression-free survival of 65 percent.",
"   </p>",
"   <p>",
"    At this time, T cell depleted transplants are not recommended outside of a clinical trial setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NONMYELOABLATIVE ALLOGENEIC HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonmyeloablative preparative regimens use less intensive chemotherapy or irradiation alone prior to the infusion of donor hematopoietic stem cells. This approach relies more on donor cellular immune effects and less on the cytotoxic effects of the preparative regimen to control the underlying disease. Nonmyeloablative allogeneic HCT and reduced intensity HCT are associated with lower rates of treatment-related toxicity and treatment-related mortality, but higher rates of relapse compared with rates previously seen with myeloablative allogeneic transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/16-22\">",
"     16-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of the graft-versus-tumor effect is supported by studies that show improved survival in patients who develop chronic graft-versus-host disease (GVHD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/23\">",
"     23",
"    </a>",
"    ]. As with myeloablative allografts, the best outcomes are seen in patients transplanted early in the course of their disease when the disease is in remission. As such, several groups are pursuing protocols in which an autologous HCT is followed by a nonmyeloablative allogeneic HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prospective trials that have investigated nonmyeloablative HCT have conflicting data regarding survival rates, but are consistent in their treatment-related mortality rates (11 to 18 percent at five years) and rates of extensive graft-versus-host disease (50 to 74 percent). New strategies are needed to improve the safety and efficacy of nonmyeloablative HCT. Until such improvements are demonstrated, this strategy is not recommended for most patients with newly diagnosed myeloma outside of a clinical trial setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/10,27\">",
"     10,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Autologous followed by nonmyeloablative allogeneic HCT in newly diagnosed myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strategy of autologous HCT followed by nonmyeloablative allogeneic HCT is not recommended for patients with newly diagnosed myeloma outside of a clinical trial setting, except perhaps in those with high-risk prognostic factors (ie, del(13), hypodiploidy, t(14;16), del(17p), or a plasma cell labeling index of &ge;3 percent). Even in such patients the role of allogeneic HCT approaches is investigational, especially given the superior results that are being obtained with newer induction regimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32584?source=see_link\">",
"     \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials of allogeneic HCT have not been feasible for patients with myeloma. Instead, investigators have relied on a \"genetic randomization\" in which patients are assigned to treatment with or without allogeneic HCT based upon the presence or absence of an HLA-matched sibling donor. Patients without an HLA-matched sibling are assigned to treatment with maintenance therapy or observation, depending upon the trial design. Results are then evaluated by an intention-to-treat analysis for \"donor\" and \"no donor\" (available) treatment groups. As with randomized trials, not all patients in the \"donor\" group ultimately receive an allogeneic HCT, but they would still be included in the \"donor\" group for the statistical analysis.",
"   </p>",
"   <p>",
"    The results of donor versus no donor trials have been mixed. While they all demonstrate lower relapse rates and higher rates of nonrelapse mortality among allogeneic HCT recipients, the majority suggests that this does not translate into a survival benefit. Of importance, options for the treatment of relapsed myeloma have increased dramatically since many of these trials were conducted. The most recent trials, some of which allowed for the use of novel agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ) at relapse, have not demonstrated a survival benefit with allogeneic HCT.",
"   </p>",
"   <p>",
"    The following are the largest trials conducted in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest study was conducted by the Bone Marrow Transplant Clinical Trials Network and enrolled 710 patients &lt;70 years with newly diagnosed myeloma who had completed at least three cycles of systemic anti-myeloma therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/28\">",
"       28",
"      </a>",
"      ]. Of the 625 patients with standard risk myeloma in this trial, 189 with an HLA-identical sibling donor were assigned to receive a myeloablative autologous HCT followed by a nonmyeloablative allogeneic HCT (completed in 83 percent). The 436 patients without a sibling donor were assigned to double autologous HCT (completed in 84 percent) followed by a second randomization to maintenance",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"        thalidomide",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"        dexamethasone",
"       </a>",
"      </span>",
"      or observation. At a median follow-up of 40 months, double autologous HCT resulted in similar rates of progression-free (46 versus 43 percent) and overall (80 versus 77 percent) survival at three years when compared with autologous HCT followed by nonmyeloablative allogeneic HCT. In the nonmyeloablative allogeneic HCT arm, grade II&ndash;IV acute graft-versus-host disease (GVHD) occurred in 26 percent of patients by day 100, including 9 percent with grade III&ndash;IV disease. The cumulative incidence of chronic GVHD was 47 percent at one year and 54 percent at two years. As with standard risk myeloma, a subgroup analysis of the 85 patients enrolled in this trial with high risk myeloma found no benefit to autologous HCT followed by nonmyeloablative allogeneic HCT. Thalidomide maintenance did not improve progression-free or overall survival.",
"     </li>",
"     <li>",
"      In the HOVON-50 multiple myeloma study, 260 patients who had received an autologous HCT were genetically assigned to receive a reduced intensity conditioning allogeneic HCT from a sibling donor (122 patients) or maintenance therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      or alpha-interferon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/29\">",
"       29",
"      </a>",
"      ]. Patients could receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , thalidomide,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      at the time of relapse. After a median follow-up of 77 months, when compared with maintenance therapy, allogeneic HCT was associated with similar rates of progression-free (28 versus 22 percent) and overall (55 percent) survival at six years. Allogeneic HCT was associated with a lower incidence of relapse (55 versus 77 percent), but higher cumulative incidence of non-relapse mortality (16 versus 3 percent) at six years. &nbsp;",
"     </li>",
"     <li>",
"      In contrast to the above two studies, an Italian study that enrolled 162 consecutive patients with newly diagnosed myeloma who were &le;65 years of age and had at least one sibling found a survival benefit with nonmyeloablative allogeneic transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/26\">",
"       26",
"      </a>",
"      ]. All patients were initially treated with two or three courses of VAD (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ) followed by 3 to 4",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      with or without 250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , following which peripheral blood stem cells were mobilized after treatment with G-CSF.",
"      <br/>",
"      <br/>",
"      Patients with an HLA-identical sibling were scheduled to",
"      <strong>",
"      </strong>",
"      receive a myeloablative autologous HCT followed by a nonmyeloablative allogeneic HCT using the sibling donor (auto-allo group). Patients without an HLA-identical sibling and those who refused allografting or whose donor was ineligible were assigned to double autologous HCT after intermediate or high dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      conditioning (auto-auto group). When compared with patients undergoing auto-auto HCT, patients undergoing auto-allo HCT had the following significant outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/26,30\">",
"       26,30",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A higher two-year cumulative incidence of treatment-related mortality (10 versus 2 percent)",
"     </li>",
"     <li>",
"      A lower cumulative incidence of disease-related mortality at a median follow-up of 45 months (43 versus 7 percent)",
"     </li>",
"     <li>",
"      Cumulative incidences of grades II to IV GVHD and grade IV GVHD of 43 and 4 percent, respectively",
"     </li>",
"     <li>",
"      A longer median overall survival (not yet reached at a median follow-up of seven years versus 4.25 years; hazard ratio 0.51, 95% CI 0.34-0.76)",
"      <br/>",
"      <br/>",
"      However, many patients in the tandem autologous transplant arm did not appear to have received the standard",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      conditioning and 46 patients with no siblings were excluded from the primary analysis and did not receive protocol therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In another trial, the French IFM group demonstrated that patients with high-risk myeloma (deletion 13 by FISH or an elevated beta-2 microglobulin level) showed no benefit with autologous HCT followed by reduced intensity allogeneic HCT compared with tandem autologous HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Spanish PETHEMA group prospectively compared the use of autologous (85 patients) or reduced-intensity allogeneic (25 patients) HCT in 110 patients with myeloma who failed to achieve a complete or near complete remission after an initial autologous HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/32\">",
"       32",
"      </a>",
"      ]. Treatment was assigned based upon the availability of HLA-identical sibling donors. At a median follow-up after second transplantation of 5.2 years of patients who received an allogeneic HCT there was no difference in event-free or overall survival rates.",
"     </li>",
"     <li>",
"      Another prospective study from the European Bone Marrow Transplantation centers evaluated 357 patients with newly diagnosed myeloma who underwent autologous HCT followed by reduced-intensity allogeneic HCT (for those who had a sibling donor, 108 patients), by a second autologous HCT (104 patients), or by observation (145 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/33\">",
"       33",
"      </a>",
"      ]. At a median follow-up of 61 months, patients who underwent allogeneic HCT had significantly higher rates of progression-free (35 versus 18 percent) and overall (65 versus 58 percent) survival at 60 months; a higher rate of nonrelapse mortality at 24 months (12 versus 3 percent); and clinically significant cumulative incidences of Grade II to IV acute GVHD (20 percent), limited chronic GVHD (31 percent) and extensive chronic GVHD (23 percent). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies demonstrate that nonmyeloablative HCT is associated with a higher cumulative incidence of nonrelapse mortality and a lower incidence of relapse; however, this does not appear to translate into a survival benefit in the setting of novel agents. Nonmyeloablative-allogeneic transplantation remains investigational. The treatment related mortality is approximately 10 to 20 percent and the rates of acute and chronic GVHD are high. It is also unclear what impact non-myeloablative HCT will have, given the major changes in induction therapy using novel agents.",
"   </p>",
"   <p>",
"    Of importance, the HOVON 76 trial evaluated nonmyeloablative allogeneic HCT followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    maintenance in 35 patients with newly diagnosed myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/34\">",
"     34",
"    </a>",
"    ]. Lenalidomide maintenance was poorly tolerated and patients also had rapid onset of graft-versus-host disease. Lenalidomide maintenance is not recommended after allogeneic HCT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=see_link&amp;anchor=H14#H14\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Lenalidomide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nonmyeloablative allogeneic HCT in relapsed myeloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of nonmyeloablative allogeneic transplantation has also been studied in patients relapsing after autologous HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/35-41\">",
"     35-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 53 patients, 33 of whom had relapsed after one or more prior autologous transplants, complete remission was attained in 62 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/36\">",
"       36",
"      </a>",
"      ]. Transplant-related mortality was 13 percent and grade III-IV acute GVHD and chronic GVHD were noted in 5 and 64 percent, respectively. At a median follow-up of 22 months, three-year estimated overall and progression-free survivals were 45 and 37 percent, respectively.",
"     </li>",
"     <li>",
"      In a larger study of 68 patients, 65 of whom had relapsed after a prior autologous HCT, complete remission rate (35 and 34 percent) and treatment-related mortality (24 and 18 percent) were similar for those with or without chromosome 13 deletion, while two-year overall survivals were 18 and 67 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/37\">",
"       37",
"      </a>",
"      ]. The higher relapse rate in patients with chromosome 13 deletion (hazard ratio: 3.3, 95% CI: 1.3-8.2) suggested the need for additional post-remission treatment, such as donor lymphocyte infusion (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Donor lymphocyte infusion'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      A retrospective analysis of 50 patients with relapsed or refractory MM treated with a",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"        fludarabine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"        melphalan",
"       </a>",
"       -based",
"      </span>",
"      conditioning regimen followed by the infusion of a graft from a related (27 patients) or unrelated donor reported a non-relapse mortality rate of 26 percent with a median follow-up time of 6.4 years. Overall and progression-free survival rates were 34 and 26 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Longer-term follow-up of these studies is awaited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MONITORING REMISSION POST-ALLOGENEIC HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be evaluated at approximately day 100 after transplantation to determine how their disease has responded to therapy. The preferred method is the measurement of monoclonal (M) protein in serum and urine. Free light chain (FLC) measurements are primarily reserved for patients with unmeasurable M-protein in the serum and urine. Among patients without an M protein in serum or urine and normal FLC ratio, further evaluation includes bone marrow immunohistochemistry or immunofluorescence and plasma cell labeling index. Blood counts, renal function, and serum calcium are also monitored. After day 100, tests for monitoring response to therapy and to detect relapse are performed every three months.",
"   </p>",
"   <p>",
"    The International Myeloma Working Group has developed uniform response criteria, which are used to measure the effect of treatment for multiple myeloma. These criteria are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31526?source=see_link\">",
"     \"Evaluating response to treatment of multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Allo HCT and complete molecular remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcome after HCT may be better assessed by evaluating the patient for complete molecular, rather than complete clinical remission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/42\">",
"     42",
"    </a>",
"    ]. This issue was addressed in a series of 48 patients in complete clinical remission following allo-HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/43\">",
"     43",
"    </a>",
"    ]. Durable polymerase chain reaction negativity for clone-specific markers, mixed negativity and positivity, or positivity were noted in 33, 40, and 27 percent, respectively. The cumulative risks for disease relapse at five years were zero, 33, and 100 percent, respectively. However, testing for molecular complete remission at present is experimental and is not available in most centers.",
"   </p>",
"   <p>",
"    In a study of 229 patients with MM, clinical complete remission (CCR) was attained in 38 and 22 percent following allogeneic or autologous HCT, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/42\">",
"     42",
"    </a>",
"    ]. For those attaining CCR following allo- or auto-HCT, 50 and 16 percent, respectively, were found to be in molecular complete remission (MCR), as defined by repeated polymerase chain reaction (PCR) negativity. Median relapse-free survivals for those who did or did not attain MCR were 110 and 35 months, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/42\">",
"     42",
"    </a>",
"    ]. Corresponding relapse rates were 16 and 41 percent, respectively.",
"   </p>",
"   <p>",
"    These results support the concept, as shown in other hematologic malignancies, that MCR is associated with longer relapse-free survival and reduced relapse rates. However, as noted above, the presence of MCR does not equate with cure. In one study of 14 patients with MM in complete remission by the EBMT criteria following high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    and autologous HCT, all were PCR negative on follow-up bone marrow examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/44\">",
"     44",
"    </a>",
"    ]. However, 8 of the 14 have since relapsed, all with the original immunoglobulin rearrangement present at disease presentation. The main limitation of MCR is that testing is not available widely and is not fully standardized.",
"   </p>",
"   <p>",
"    Similar results can perhaps be obtained by monitoring for the presence of neoplastic plasma cells in bone marrow aspirates post-HCT, using flow cytometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/45\">",
"     45",
"    </a>",
"    ]. The 12 patients in the \"low risk\" group (ie, no malignant cells at both three and six months post-transplant) had a five-year overall survival of 100 percent, while the 23 patients in the \"high risk\" group (ie, either malignant cells at three months or no malignant cells at three months reverting to malignant cells at six months) had a five-year survival of 54 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT OF RELAPSE AFTER HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for relapsed multiple myeloma after an allogeneic HCT include donor lymphocyte infusion or treatment with salvage chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Donor lymphocyte infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor lymphocyte infusion (DLI) produces significant clinical benefit in many patients with MM relapsing after allogeneic HCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/46\">",
"     46",
"    </a>",
"    ]. In a series of 54 patients, DLI yielded overall and complete response rates of 52 and 17 percent, and acute and chronic GVHD in 57 and 47 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/47\">",
"     47",
"    </a>",
"    ]. Progression-free survival was 20 months for partial responders, and had not been reached for those achieving complete remission. Predictive factors for response to DLI were remission before allo-HCT and the occurrence of acute or chronic graft-versus-host disease. Of interest, deletion of chromosome 13 did not influence response or outcome following DLI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=see_link\">",
"     \"Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one exploratory study, use of",
"    <strong>",
"     prophylactic",
"    </strong>",
"    DLI with CD4+ cells at six months following HCT enhanced reconstitution of donor T cells and conversion to full donor hematopoiesis, as well as promoting antitumor immunity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 18 patients with progressive or residual disease and prior ineffective DLI after allogeneic HCT, adoptive therapy with low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      plus DLI achieved an overall response rate of 67 percent with a low incidence of acute and chronic GVHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, objective responses to salvage treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      were noted in 9 of 31 patients with myeloma progressing after allogeneic HCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36296/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At present, patients with multiple myeloma should be aware of the availability, and encouraged to undergo, autologous hematopoietic cell transplantation (HCT) if they are eligible for the procedure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=see_link&amp;anchor=H7#H7\">",
"       \"Determination of initial therapy in patients with multiple myeloma\", section on 'Determining transplant eligibility'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myeloablative allogeneic HCT is associated with too high a mortality and is generally not recommended at this time outside of clinical trials. Efforts to reduce allogeneic HCT-related mortality with the use of non-myeloablative regimens also remain investigational. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24792?source=see_link\">",
"       \"Prevention of acute graft-versus-host disease: Trials of T cell depletion\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"       \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of maintenance therapy, dendritic cells, and vaccines following allogeneic HCT is under investigation.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/1\">",
"      Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/2\">",
"      Mehta J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplant 1998; 22:835.",
"     </a>",
"    </li>",
"    <li>",
"     Gahrton G, Tura S, Svensson H, et al. Allogeneic bone marrow transplantation in multiple myeloma: an update of the EBMT Registry. VIth International Workshop on Multiple Myeloma, Syllabus, Boston, MA, June 14-18, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/4\">",
"      Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/5\">",
"      Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/6\">",
"      Gahrton G, Bj&ouml;rkstrand B. Progress in haematopoietic stem cell transplantation for multiple myeloma. J Intern Med 2000; 248:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/7\">",
"      Bensinger WI, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol 2001; 38:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/8\">",
"      Shaw BE, Peggs K, Bird JM, et al. The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. Br J Haematol 2003; 123:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/9\">",
"      UK myeloma forum. British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 115:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/10\">",
"      Lokhorst H, Einsele H, Vesole D, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010; 28:4521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/11\">",
"      Gahrton G, Svensson H, Bj&ouml;rkstrand B, et al. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1999; 24:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/12\">",
"      Fefer A, Cheever MA, Greenberg PD. Identical-twin (syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst 1986; 76:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/13\">",
"      D'Sa S, Peggs K, Pizzey A, et al. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. Br J Haematol 2003; 123:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/14\">",
"      Lokhorst HM, Segeren CM, Verdonck LF, et al. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 2003; 21:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/15\">",
"      Alyea E, Weller E, Schlossman R, et al. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001; 98:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/16\">",
"      Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/17\">",
"      Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002; 20:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/18\">",
"      Branson K, Chopra R, Kottaridis PD, et al. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002; 20:4022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/19\">",
"      Kr&ouml;ger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100:3919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/20\">",
"      P&eacute;rez-Sim&oacute;n JA, Martino R, Alegre A, et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003; 121:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/21\">",
"      Crawley C, Iacobelli S, Bj&ouml;rkstrand B, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109:3588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/22\">",
"      Kumar S, Zhang MJ, Li P, et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood 2011; 118:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/23\">",
"      Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005; 105:4532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/24\">",
"      Kr&ouml;ger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/25\">",
"      Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102:3447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/26\">",
"      Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/27\">",
"      Stewart AK. Reduced-intensity allogeneic transplantation for myeloma: reality bites. Blood 2009; 113:3135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/28\">",
"      Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/29\">",
"      Lokhorst HM, van der Holt B, Cornelissen JJ, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012; 119:6219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/30\">",
"      Giaccone L, Storer B, Patriarca F, et al. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood 2011; 117:6721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/31\">",
"      Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107:3474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/32\">",
"      Rosi&ntilde;ol L, P&eacute;rez-Sim&oacute;n JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112:3591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/33\">",
"      Bj&ouml;rkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011; 29:3016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/34\">",
"      Kneppers E, van der Holt B, Kersten MJ, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. Blood 2011; 118:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/35\">",
"      Einsele H, Sch&auml;fer HJ, Hebart H, et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/36\">",
"      Majolino I, Davoli M, Carnevalli E, et al. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma 2007; 48:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/37\">",
"      Kr&ouml;ger N, Schilling G, Einsele H, et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004; 103:4056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/38\">",
"      de Lavallade H, El-Cheikh J, Faucher C, et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008; 41:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/39\">",
"      Kr&ouml;ger N, Shimoni A, Schilling G, et al. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Br J Haematol 2010; 148:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/40\">",
"      Shimoni A, Hardan I, Ayuk F, et al. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. Cancer 2010; 116:3621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/41\">",
"      Nivison-Smith I, Dodds AJ, Doocey R, et al. Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome. Leuk Lymphoma 2011; 52:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/42\">",
"      Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000; 18:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/43\">",
"      Corradini P, Cavo M, Lokhorst H, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/44\">",
"      Davies FE, Forsyth PD, Rawstron AC, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001; 112:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/45\">",
"      Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002; 100:3095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/46\">",
"      Kr&ouml;ger N, Kr&uuml;ger W, Renges H, et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001; 112:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/47\">",
"      Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103:4362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/48\">",
"      Bellucci R, Alyea EP, Weller E, et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood 2002; 99:4610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/49\">",
"      Kr&ouml;ger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004; 104:3361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36296/abstract/50\">",
"      Mohty M, Attal M, Marit G, et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du My&eacute;lome (IFM) and the Soci&eacute;t&eacute; Fran&ccedil;aise de Greffe de Moelle et Th&eacute;rapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005; 35:165.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6667 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36296=[""].join("\n");
var outline_f35_28_36296=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MYELOABLATIVE HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SYNGENEIC HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      T CELL DEPLETED ALLOGENEIC HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NONMYELOABLATIVE ALLOGENEIC HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Autologous followed by nonmyeloablative allogeneic HCT in newly diagnosed myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nonmyeloablative allogeneic HCT in relapsed myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MONITORING REMISSION POST-ALLOGENEIC HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Allo HCT and complete molecular remission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT OF RELAPSE AFTER HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Donor lymphocyte infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31526?source=related_link\">",
"      Evaluating response to treatment of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16298?source=related_link\">",
"      Immunotherapy for the prevention and treatment of relapse following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/52/32584?source=related_link\">",
"      Initial chemotherapy for patients with high risk multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24792?source=related_link\">",
"      Prevention of acute graft-versus-host disease: Trials of T cell depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_28_36297="Fosamprenavir: Pediatric drug information";
var content_f35_28_36297=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fosamprenavir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"    see \"Fosamprenavir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/5/32853?source=see_link\">",
"    see \"Fosamprenavir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lexiva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Telzir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Protease Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12864280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not approved for use; appropriate dose is unknown.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"      see \"Fosamprenavir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (use in combination with other antiretroviral agents);",
"     <b>",
"      Note:",
"     </b>",
"     Dosing is based on whether patient is antiretroviral therapy-na&iuml;ve or experienced and on concomitant therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children &lt;2 years: Not approved for use; appropriate dose is unknown",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-18 years: Do not exceed adult dose;",
"     <b>",
"      Note:",
"     </b>",
"     Once-daily dosing of fosamprenavir is",
"     <b>",
"      not",
"     </b>",
"     recommended in pediatric patients (data from a pediatric once-daily dosing study of fosamprenavir plus ritonavir were insufficient to support once-daily dosing in any pediatric patient population).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Antiretroviral therapy-na&iuml;ve pediatric patients:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-5 years: Unboosted regimen (ie, regimen without ritonavir): Fosamprenavir 30 mg/kg/dose twice daily; maximum dose: 1400 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;6 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Unboosted regimen (ie, regimen without ritonavir): Fosamprenavir 30 mg/kg/dose twice daily; maximum dose: 1400 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ritonavir boosted regimen: Fosamprenavir 18 mg/kg/dose (maximum dose: 700 mg) twice daily plus ritonavir 3 mg/kg/dose (maximum dose: 100 mg) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Protease inhibitor-experienced pediatric patients:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-5 years: Not approved for use; appropriate dose is unknown",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;6 years and Adolescents: Ritonavir boosted regimen: Fosamprenavir 18 mg/kg/dose (maximum dose: 700 mg) twice daily plus ritonavir 3 mg/kg/dose (maximum dose: 100 mg) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The unboosted adult regimen of 1400 mg twice daily may be used for pediatric patients who weigh &ge;47 kg. When combined with ritonavir, fosamprenavir tablets may be administered to children who weigh &ge;39 kg; ritonavir capsules may be used for pediatric patients who weigh &ge;33 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Antiretroviral therapy-na&iuml;ve adult patients:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Unboosted regimen (ie, regimen without ritonavir): Fosamprenavir 1400 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ritonavir boosted regimens:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Once-daily regimens:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Fosamprenavir 1400 mg once daily plus ritonavir 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Fosamprenavir 1400 mg once daily plus ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Twice-daily regimen: Fosamprenavir 700 mg twice daily plus ritonavir 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Protease inhibitor-experienced adult patients:",
"     </b>",
"     Fosamprenavir 700 mg twice daily plus ritonavir 100 mg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Once-daily dosing of fosamprenavir is not recommended in protease inhibitor-experienced patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Concomitant therapy with efavirenz:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Only ritonavir-boosted regimens should be used when efavirenz is used in combination with fosamprenavir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Once-daily regimen: Fosamprenavir 1400 mg once daily plus ritonavir 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Twice-daily regimen: Fosamprenavir 700 mg twice daily plus ritonavir 100 mg twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     No change in ritonavir dosage is required when patients receive efavirenz with twice-daily dosing of fosamprenavir with ritonavir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Concomitant therapy with nevirapine: Note:",
"     </b>",
"     Only ritonavir-boosted regimens should be used when nevirapine is used in combination with fosamprenavir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Once-daily regimen: Not studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Twice-daily regimen: Fosamprenavir 700 mg twice daily plus ritonavir 100 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Use with caution: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment (Child-Pugh score 5-6): Reduce dosage of fosamprenavir to 700 mg twice daily without concurrent ritonavir (therapy-na&iuml;ve) or fosamprenavir 700 mg twice daily plus ritonavir 100 mg once daily (therapy-na&iuml;ve or PI-experienced)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate impairment (Child-Pugh score 7-9): Reduce dosage of fosamprenavir to 700 mg twice daily without concurrent ritonavir (therapy-na&iuml;ve) or fosamprenavir 450 mg twice daily plus ritonavir 100 mg once daily (therapy-na&iuml;ve or PI-experienced)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment (Child-Pugh score 10-15): Reduce dosage of fosamprenavir to 350 mg twice daily without concurrent ritonavir (therapy na&iuml;ve) or use fosamprenavir 300 mg twice daily plus ritonavir 100 mg once daily (therapy na&iuml;ve or protease inhibitor  experienced).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lexiva&reg;: 50 mg/mL (225 mL) [contains propylene glycol; grape-bubblegum-peppermint flavor; equivalent to amprenavir ~43 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lexiva&reg;: 700 mg [equivalent to amprenavir ~600 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer concurrently with antacids or buffered formulations of other medications (separate administration by 1 hour).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral suspension: Administer",
"     <b>",
"      with",
"     </b>",
"     food to pediatric patients; administer",
"     <b>",
"      without",
"     </b>",
"     food to adults. Readminister dose of suspension if emesis occurs within 30 minutes after dosing. Shake suspension vigorously prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral suspension: Store at 5&deg;C to 30&deg;C (41&deg;F to 86&deg;F). Do not freeze. Refrigeration is not required, but it may improve the taste of the suspension for some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Tablets: Store at controlled room temperature of 25&deg;C (77&deg;F) in tightly closed container; excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection in combination with other antiretroviral agents (FDA approved in therapy-na&iuml;ve patients ages &ge;2 years and adults and in therapy-experienced patients ages &ge;6 years and adults) (",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F174278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lexiva&reg; may be confused with Levitra&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F174277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash (onset: ~11 days; duration: ~13 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypertriglyceridemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, serum lipase increased, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia",
"    </p>",
"    <p style=\"text-indent:-6em;margin-left:6em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Angioedema, hypercholesterolemia, myocardial infarction, nephrolithiasis, oral paresthesia, QT prolongation (with amprenavir),  Stevens-Johnson syndrome, stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined: Diabetes mellitus, fat redistribution, and immune reconstitution syndrome have been associated with protease inhibitor therapy. Spontaneous bleeding has been reported in patients with hemophilia A or B following treatment with protease inhibitors. Acute hemolytic anemia has been reported in association with amprenavir use.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fosamprenavir, amprenavir, or any component; concurrent therapy with CYP3A4 substrates with a narrow therapeutic window; concomitant  therapy with cisapride, delavirdine, dihydroergotamine, ergonovine, ergotamine, methylergonovine, lovastatin, midazolam, pimozide, rifampin, simvastatin, St John&rsquo;s wort, and triazolam; if fosamprenavir is administered with ritonavir, flecainide and propafenone are also contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with diabetes mellitus, sulfonamide allergy (fosamprenavir is a sulfonamide), or hemophilia. Use with caution and decrease the dose in patients with hepatic impairment; patients coinfected with hepatitis B or C and those with baseline liver enzyme elevation may be at risk for elevated liver enzymes with fosamprenavir therapy. Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established). Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents; this syndrome may require further patient assessment and therapy. Safety and efficacy have not been established in children &lt;2 years of age. May cause vomiting; reported in 30% of pediatric patients (regardless of causality) receiving fosamprenavir twice daily with ritonavir (compared to 10% of adults) and occurred in 56% of children 2-5 years of age receiving twice daily fosamprenavir without ritonavir (compared to 16% of adults).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Animal studies indicate that fosamprenavir may be carcinogenic and may possess abortifacient properties; minor skeletal abnormalities have been observed in the offspring when amprenavir was administered to pregnant rabbits; the relevance for humans of these animal studies is uncertain.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fosamprenavir (a prodrug of amprenavir) is a potent CYP3A4 isoenzyme inhibitor that interacts with numerous drugs. Due to potential serious and/or life-threatening drug interactions, some drugs are contraindicated and the following drugs require serum concentration monitoring if coadministered with fosamprenavir: Amiodarone, systemic lidocaine, tricyclic antidepressants, and quinidine. Concurrent use with rifampin, St John's wort, certain cholesterol-lowering agents (lovastatin, simvastatin), and delavirdine are contraindicated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Rash may occur (incidence: ~19%); usually mild to moderate, maculopapular, some pruritic; median onset: 11 days, median duration: 13 days. Severe and life-threatening skin reactions (including Stevens-Johnson syndrome) may occur (&lt;1% of patients); discontinue fosamprenavir in patients who develop severe or life-threatening rashes or in patients with moderate rashes and systemic symptoms. Acute hemolytic anemia has been reported. Spontaneous bleeding episodes have been reported in patients with hemophilia type A and B receiving protease inhibitors. New-onset diabetes mellitus, exacerbations of diabetes, and hyperglycemia have been reported in HIV-infected patients receiving protease inhibitors. Higher than recommended combination doses of fosamprenavir and ritonavir may result in increased risk of transaminase elevations. Cases of nephrolithiasis have been reported with fosamprenavir use; consider temporary or permanent discontinuation of therapy if symptoms develop.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Significant elevations of serum triglycerides and cholesterol may occur; obtain serum triglyceride and cholesterol prior to initiation of therapy and periodically thereafter; manage lipid elevations appropriately. Modifiable risk factors for cardiovascular disease (eg, smoking, diabetes, hypertension) should also be monitored and managed appropriately. A possible increased risk of MI may occur in adult patients with HIV receiving fosamprenavir. Data recently reported from a nested case-control study linked cumulative fosamprenavir exposure to an increased risk of MI [OR = 1.52 per additional year of exposure (95% CI: 1.19-1.95)]. Previously, the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study identified a possible association between MI and the use of protease inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F174267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Fosamprenavir. Fosamprenavir may increase the serum concentration of Bosentan. Management: Use bosentan 62.5 mg/day or every other day in adult patients taking fosamprenavir for at least 10 days.  Temporarily stop bosentan (for at least 36 hrs) before starting fosamprenavir; wait at least 10 days before restarting bosentan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clorazepate: Fosamprenavir may increase the serum concentration of Clorazepate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: Fosamprenavir may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are receiving ritonavir-boosted fosamprenavir.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Fosamprenavir. Specifically, delavirdine may increase concentrations of the active metabolite amprenavir. Fosamprenavir may decrease the serum concentration of Delavirdine. The active metabolite amprenavir is likely responsible for this effect.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazepam: Fosamprenavir may increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease serum concentrations of the active metabolite(s) of Fosamprenavir. Management: For once-daily fosamprenavir/ritonavir with efavirenz, an increased ritonavir dose to 300 mg/day is recommended.  No ritonavir dose adjustment is required if using twice-daily fosamprenavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may increase.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Fosamprenavir may increase the serum concentration of Flecainide.  Management: Concurrent use of ritonavir-boosted fosamprenavir with flecainide is contraindicated.  The use of non-ritonavir-boosted fosamprenavir with flecainide is not specifically contraindicated but should only be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flurazepam: Fosamprenavir may increase the serum concentration of Flurazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Fosamprenavir may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Itraconazole. Management: Limit the adult maximum itraconazole dose to 200 mg/day with fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, patients receiving greater than 400 mg/day itraconazole may also require dose reduction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Ketoconazole (Systemic). Management: Limit the adult maximum ketoconazole dose to 200 mg/day with fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, patients receiving greater than 400 mg/day ketoconazole may also require dose reduction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: Fosamprenavir may decrease the serum concentration of Lopinavir. Specifically, amprenavir (the active metabolite of fosamprenavir) may decrease the serum concentration of lopinavir.  Management: Lopinavir/ritonavir should not be used as a once daily regimen when used together with fosamprenavir.  The use of ritonavir-boosted fosamprenavir with lopinavir/ritonavir may negate this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Protease Inhibitors may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease serum concentrations of the active metabolite(s) of Fosamprenavir. Management: Coadministration of nevirapine and fosamprenavir is not recommended without concurrent ritonavir.  However, when nevirapine and fosamprenavir/ritonavir (twice daily) are used in combination, no dose adjustment is required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PARoxetine: Fosamprenavir may decrease the serum concentration of PARoxetine. The active metabolite amprenavir is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Fosamprenavir may decrease the serum concentration of Phenytoin. The active amprenavir metabolite is likely responsible for this effect. Phenytoin may increase the serum concentration of Fosamprenavir. Specifically, phenytoin may increase the concentration of the active metabolite amprenavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase serum concentrations of the active metabolite(s) of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Fosamprenavir may increase the serum concentration of Propafenone.  Management: Concurrent use of ritonavir-boosted fosamprenavir with propafenone is contraindicated.  The use of non-ritonavir-boosted fosamprenavir with propafenone is not specifically contraindicated but should only be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Fosamprenavir may decrease the serum concentration of Raltegravir. Raltegravir may decrease the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Fosamprenavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Fosamprenavir may increase the serum concentration of Rifabutin. Rifabutin may increase the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Fosamprenavir. Specifically, concentrations of amprenavir (active metabolite) may be decreased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Fosamprenavir may decrease the serum concentration of Telaprevir. Telaprevir may decrease the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Fosamprenavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with fosamprenavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Fosamprenavir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1053040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral suspension: In adults, a standardized high-fat meal decreased the peak concentration by 46%, delayed the time to peak by 0.72 hours, and decreased the amprenavir AUC by 28% compared with the fasted state.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Tablets: Food does not significantly affect absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F174239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. It is not known if fosamprenavir crosses the human placenta. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and protease inhibitors (PIs) should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk. The DHHS Perinatal HIV Guidelines note there are insufficient data to recommend use during pregnancy; however, if used, they recommend that fosamprenavir be given with low-dose ritonavir boosting.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of rash or adverse effects; serum glucose, triglycerides, cholesterol, liver enzymes, CBC with differential, CD4 cell count, viral load",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fosamprenavir is rapidly converted to amprenavir",
"     <i>",
"      in vivo",
"     </i>",
"     . Amprenavir is a protease inhibitor which acts on an enzyme (protease) late in the HIV replication process after the virus has entered into the cell's nucleus; amprenavir binds to the protease activity site and inhibits the activity of the enzyme, thus preventing cleavage of viral polyprotein precursors (gag-pol protein precursors) into individual functional proteins found in infectious HIV; this results in the formation of immature, noninfectious viral particles",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 90%; primarily to alpha",
"     <sub>",
"      1",
"     </sub>",
"     acid glycoprotein; concentration-dependent binding; protein binding is decreased in patients with hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Fosamprenavir is the prodrug of amprenavir; fosamprenavir is rapidly hydrolyzed to amprenavir and inorganic phosphate by cellular phosphatases in the gut epithelium as it is absorbed; amprenavir is metabolized in the liver via cytochrome P450 CYP3A4 isoenzyme system; glucuronide conjugation of oxidized metabolites also occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Absolute oral bioavailability is not established. Similar amprenavir AUCs occurred in adults when single doses of the oral suspension versus tablets were administered in the fasted state; however, the suspension provided a 14.5% higher peak concentration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Amprenavir: Adults: 7.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Amprenavir (single dose of fosamprenavir): Median: 2.5 hours; range: 1.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Minimal excretion of unchanged drug in urine (1%) and feces; 75% of dose excreted as metabolites via biliary tract into feces and 14% excreted as metabolites in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Peritoneal or hemodialysis:  Amount removed is not known",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/5/32853?source=see_link\">",
"      see \"Fosamprenavir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform your physician if you have a sulfa allergy. Notify physician immediately if rash develops. Some medicines should not be taken with fosamprenavir; report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist. Avoid the herbal medicine St John's wort; use alternate contraceptive measures instead of hormonal contraception (ie, the birth control pill) during therapy with fosamprenavir (hormonal contraceptives may not be effective if taken with fosamprenavir and liver enzymes may increase if hormonal contraceptives are taken with fosamprenavir plus ritonavir). Fosamprenavir is not a cure for HIV. Take fosamprenavir every day as prescribed; do not change dose or discontinue without physician's advice; if a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do not double the next dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Kidney stones may occur in some patients; notify physician immediately if you develop pain in your side or when you urinate, or blood in your urine. HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral suspension contains 50 mg/mL of fosamprenavir as fosamprenavir calcium and is equivalent to amprenavir 43 mg/mL. Fosamprenavir calcium 700 mg (1 tablet) is approximately equal to amprenavir 600 mg.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Briars LA, Hilao JJ, and Kraus DM, &ldquo;A Review of Pediatric Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Journal of Pharmacy Practice",
"      </i>",
"      , 2004, 17(6):407-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman TM, Plosker GL, and Perry CM, &ldquo;Fosamprenavir: A Review of Its Use in the Management of Antiretroviral Therapy-Naive Patients With HIV Infection,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2004, 64(18):2101-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/28/36297/abstract-text/15341507/pubmed\" id=\"15341507\" target=\"_blank\">",
"        15341507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" October 14, 2011, 1-167. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" August 11, 2011. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morris JL and Kraus DM, \"New Antiretroviral Therapies for Pediatric HIV Infection,\"",
"      <i>",
"       J Pediatr Pharmacol Ther",
"      </i>",
"      , 2005, 10:215-47.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wire MB, Shelton MJ, and Studenberg S, \"Fosamprenavir: Clinical Pharmacokinetics and Drug Interactions of the Amprenavir Prodrug,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2006, 45(2):137-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/28/36297/abstract-text/16485915/pubmed\" id=\"16485915\" target=\"_blank\">",
"        16485915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12930 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36297=[""].join("\n");
var outline_f35_28_36297=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174255\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855138\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053030\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12864280\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053023\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174232\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174220\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053034\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053026\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053033\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174278\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174277\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053037\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053022\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053021\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174267\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174227\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053040\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174229\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174239\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053029\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053020\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053036\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053028\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053038\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12930\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12930|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=related_link\">",
"      Fosamprenavir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/5/32853?source=related_link\">",
"      Fosamprenavir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_28_36298="Treatment of chronic functional constipation and fecal incontinence in infants and children";
var content_f35_28_36298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of chronic functional constipation and fecal incontinence in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/28/36298/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/28/36298/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/28/36298/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/28/36298/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/28/36298/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/28/36298/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/28/36298/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation is common among children, accounting for an estimated 3 to 5 percent of all visits to pediatricians. Functional constipation is an umbrella term that encompasses a group of disorders associated with persistent, difficult, infrequent, or seemingly incomplete defecation without evidence of a structural or biochemical explanation (",
"    <a class=\"graphic graphic_table graphicRef57882 \" href=\"mobipreview.htm?23/14/23788\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fecal incontinence, also known as encopresis or soiling, refers to the repetitive (voluntary or involuntary) passage of stool in inappropriate places by children four years of age and older, at which time a child may be reasonably expected to have completed toilet training and to exercise bowel control. Fecal incontinence is usually associated with chronic constipation and functional fecal retention. However, it may occur in the absence of fecal retention, in which case it is termed non-retentive fecal incontinence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44182?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children\", section on 'Definition and classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of chronic functional constipation and fecal incontinence in infants and children will be discussed here. The etiology and diagnosis of constipation, the prevention and treatment of acute constipation, and the clinical manifestations and evaluation of children with fecal incontinence are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=see_link\">",
"     \"Constipation in children: Etiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2710?source=see_link\">",
"     \"Prevention and treatment of acute constipation in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44182?source=see_link\">",
"     \"Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT OF INFANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation is treated somewhat differently in infants as compared to children. When constipation presents early in life, the clinician should be particularly alert for evidence of organic disease, including cystic fibrosis and Hirschsprung disease. Guidelines and an algorithm for diagnosing and treating constipation in infants were developed by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN), and are included in a",
"    <a class=\"external\" href=\"file://www.naspghan.org/user-assets/Documents/pdf/PositionPapers/constipation.guideline.2006.pdf\">",
"     Clinical Practice Guideline",
"    </a>",
"    at the society's Web site (",
"    <a class=\"external\" href=\"file://www.naspghan.org/\">",
"     www.naspghan.org",
"    </a>",
"    ). The functional and organic causes of constipation in infants are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=see_link&amp;anchor=H5#H5\">",
"     \"Constipation in children: Etiology and diagnosis\", section on 'Functional versus organic'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with functional constipation frequently respond to treatment with non-digestible osmotically active carbohydrates, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    -containing juices. Dark corn syrup has been used in the past. However, current preparations of dark corn syrup may not contain the glycoproteins that are fermented into osmotically active particles in the colon, so the syrup may be ineffective for treating constipation. If these measures are unsuccessful, addition of osmotic laxatives",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    occasional disimpaction with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/10/26787?source=see_link\">",
"     glycerin",
"    </a>",
"    suppositories can be useful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2710?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevention and treatment of acute constipation in infants and children\", section on 'Acute constipation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2710?source=see_link&amp;anchor=H9#H9\">",
"     \"Prevention and treatment of acute constipation in infants and children\", section on 'Recurrent constipation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Laxatives'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The choice of medications for treatment of functional constipation in infants is similar to that in children. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Treatment of children'",
"    </a>",
"    below.) However, there are some important differences in treatment decisions for infants:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osmotic laxatives such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/24/39299?source=see_link\">",
"       lactulose",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"       sorbitol",
"      </a>",
"      are frequently used and are usually effective in infants. The use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/38/25189?source=see_link\">",
"       polyethylene glycol",
"      </a>",
"      without electrolytes (PEG-3350, or Miralax&reg;) for infants &lt;24 months of age was reported in two small case series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. The treatment was generally effective and no adverse effects were noted in either study. The mean effective maintenance dose was approximately 0.8",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      body weight per day. Thus, experience with polyethylene glycol is increasing in infants, although the safety is less well established than with older age groups.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/28/20931?source=see_link\">",
"       Mineral oil",
"      </a>",
"      is not recommended in infants, or in other children prone to gastroesophageal reflux, because of potential risks of pneumonitis if aspirated.",
"     </li>",
"     <li>",
"      Use of enemas and stimulant laxatives (such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/56/42883?source=see_link\">",
"       bisacodyl",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/1/42003?source=see_link\">",
"       senna",
"      </a>",
"      ) are also not recommended in this age group because of potential complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT OF CHILDREN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of chronic functional constipation and fecal incontinence should be tailored to the severity of constipation and the child's developmental stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4\">",
"     4",
"    </a>",
"    ]. A comprehensive program, including the use of laxatives, behavior changes, dietary changes, and close follow-up is often necessary, particularly for children who have gone several days between bowel movements, have an anal fissure with bleeding, or have very large-diameter stools with marked straining [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. A suggested treatment plan for children with chronic constipation but without overflow incontinence that can be printed out and given to parents is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef61175 \" href=\"mobipreview.htm?33/43/34491\">",
"     table 2",
"    </a>",
"    ). A suggested treatment plan for children with chronic constipation and fecal incontinence is provided separately (",
"    <a class=\"graphic graphic_table graphicRef54749 \" href=\"mobipreview.htm?0/50/813\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The goal of therapy is the achievement of one soft stool per day. Weeks to months, and sometimes years, of laxative and behavior therapy may be necessary before this goal is achieved. Nonetheless, improvement can be expected in most patients. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The combined laxative and behavioral approach has been used since the 1960s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/11\">",
"     11",
"    </a>",
"    ]. It has been evaluated in only a few controlled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/12-14\">",
"     12-14",
"    </a>",
"    ] but is largely supported by cohort studies, case-control studies, and clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/15-22\">",
"     15-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analysis of intervention trials is complicated by the varied methods used for laxative and behavioral treatments. Consequently, conclusions also vary, but generally support the use of combination therapy with both of these modalities. As an example, a large study found that the combination of behavioral intervention and laxative therapy was more effective than behavioral therapy alone (achievement of remission: 63 versus 43 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/12\">",
"     12",
"    </a>",
"    ]. Another study showed that combination therapy was more effective than laxative therapy alone (improvement rates: 78 versus 45 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/13\">",
"     13",
"    </a>",
"    ], whereas a similar randomized study did not show such an effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/23\">",
"     23",
"    </a>",
"    ]. A systematic review concluded that combined behavioral and laxative treatment was more effective than either intervention alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/9\">",
"     9",
"    </a>",
"    ]. Evidence supporting biofeedback was lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/9,13\">",
"     9,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines for management of infants and children with constipation were developed by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN), and were endorsed by the American Academy of Pediatrics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ]. These guidelines include a management algorithm, and are available as a",
"    <a class=\"external\" href=\"file://www.naspghan.org/user-assets/Documents/pdf/PositionPapers/constipation.guideline.2006.pdf\">",
"     Clinical Practice Guideline",
"    </a>",
"    at the society's Web site (",
"    <a class=\"external\" href=\"file://www.naspghan.org/\">",
"     www.naspghan.org",
"    </a>",
"    ). The position statement recommends the following actions in children with functional constipation for more than two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Provide parental education.",
"     </li>",
"     <li>",
"      Determine whether impaction is present.",
"     </li>",
"     <li>",
"      Remove the impaction via oral or rectal medication.",
"     </li>",
"     <li>",
"      Start maintenance therapy with laxatives, behavior modification, and dietary changes; adjust laxatives as necessary.",
"     </li>",
"     <li>",
"      Provide close follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections will provide further detail in some of the elements involved in the care of these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective education of the parents and child with regard to constipation is crucial in changing chronic behavior patterns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. Treatment requires a team approach involving the patient, family, and healthcare provider [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/17\">",
"     17",
"    </a>",
"    ]. A primary goal is to remove negative attributions. The parent or caretaker must understand that soiling due to overflow incontinence does not constitute willful and defiant behavior by the child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ]. The child should not be scolded, or otherwise punished, for soiling episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The child's parent or caretaker should be provided with verbal and printed information. Printed information should be written in easy-to-understand, lay language, with helpful diagrams and descriptions of the problem and the methods that will be used to solve it (",
"    <a class=\"graphic graphic_figure graphicRef74718 \" href=\"mobipreview.htm?15/2/15397\">",
"     figure 1",
"    </a>",
"    ). Because there is often a concern about the safety of long-term laxative use, it is important to explain the need for laxatives and the safety of the type of laxative that will be prescribed.",
"   </p>",
"   <p>",
"    It is helpful for parents to understand how and why the constipation became chronic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/13,24,26\">",
"     13,24,26",
"    </a>",
"    ]. Once the constipation has been relieved, it may be some time before the stretched rectal muscles and changes in rectal perception readjust and the child learns how to properly coordinate the newly conditioned muscles. The predominant theme of the management program is that of rebuilding the rectal muscles to control the bowels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/25\">",
"     25",
"    </a>",
"    ]. In toddlers, toilet training should be postponed, since it will not be successful until rectal awareness is restored and defecation is pain free [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Bowel retraining'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=see_link&amp;anchor=H6#H6\">",
"     \"Constipation in children: Etiology and diagnosis\", section on 'Etiology of functional constipation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, parents should be apprised that this process can take as long as six months to several years. Regular follow-up and ongoing support and encouragement to the parents and child during periodic office visits or phone conversations are essential. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     School issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;In severe cases, the parents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinician may need to enlist the help of the school and teacher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/25\">",
"     25",
"    </a>",
"    ]. Some children may benefit from access to a private bathroom. The teacher should be sensitive to the child's problem, permitting him or her to use the bathroom whenever requested (often by a prearranged, unobtrusive signal to avoid drawing attention). In addition, it may be helpful to have a change of clothing available in case a soiling episode occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Bowel retraining",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four general steps in achieving bowel retraining.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaction should be relieved.",
"     </li>",
"     <li>",
"      Laxatives should be administered with the goal of achieving one daily bowel movement.",
"     </li>",
"     <li>",
"      Laxatives should be discontinued gradually once the child's bowel becomes conditioned to work properly on its own.",
"     </li>",
"     <li>",
"      The diet should be changed to prevent further constipation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Disimpaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with fecal retention, disimpaction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    catharsis are usually necessary before maintenance therapy can begin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10,24,27\">",
"     10,24,27",
"    </a>",
"    ]. Disimpaction and catharsis can be effectively accomplished with oral or nasogastric medications, rectal medications, or a combination. The parents and child should be involved in the decision regarding the appropriate route [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10,28\">",
"     10,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disimpaction can usually be performed in the outpatient setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/24\">",
"     24",
"    </a>",
"    ]. It is important to assess the response to the regimen as soon as possible after it is completed. Successful catharsis is usually indicated by parental report of abundant fecal production and decreased episodes of soiling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hospitalization may be necessary if several attempts of outpatient management have failed to yield abundant stool. Inpatient regimens may include the combination of an enema and suppository, or the nasogastric administration of a balanced electrolyte solution (ie, GoLYTELY) to flush out the colon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/24\">",
"     24",
"    </a>",
"    ]. Pulsed irrigation enhanced-evacuation systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/29\">",
"     29",
"    </a>",
"    ] and enemas with Gastrografin and Tween-80 (a nonionic surfactant solution) are other techniques that have been successfully used for disimpaction in cases of stool retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. These enemas can be administered in or out of the hospital. Consultation with a pediatric gastroenterologist should be considered if disimpaction is unsuccessful or if hospitalization is necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10191107\">",
"    <span class=\"h4\">",
"     Oral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral medications for disimpaction are noninvasive and may help the child feel in control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ]. Oral medications are usually preferred for children with a history of painful defecation, perineal trauma, or the inability to tolerate enemas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4,28\">",
"     4,28",
"    </a>",
"    ]. However, adherence with the necessary volume may be difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/38/25189?source=see_link\">",
"     Polyethylene glycol",
"    </a>",
"    without electrolytes, polyethylene glycol-electrolyte solutions, or high-dose",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/28/20931?source=see_link\">",
"     mineral oil",
"    </a>",
"    has been shown to be effective for initial disimpaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/28,33-37\">",
"     28,33-37",
"    </a>",
"    ]. The polyethylene glycol without electrolytes is generally the most palatable of these options and better accepted by children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ]. The doses are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/38/25189?source=see_link\">",
"       Polyethylene glycol",
"      </a>",
"      <strong>",
"       without electrolytes",
"      </strong>",
"      (PEG 3350 powder; Miralax&reg; and others) &mdash; 1 to 1.5",
"      <span class=\"nowrap\">",
"       gm/kg/day",
"      </span>",
"      for three days. The daily dose is dissolved in approximately 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of water or flavored beverage. In a randomized placebo-controlled study, these doses successfully disimpacted 95 percent of children with chronic constipation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/36\">",
"       36",
"      </a>",
"      ]. Of note, PEG 3350 was found to be as effective as enemas in treating impaction, but children treated with PEG had more fecal incontinence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/37\">",
"       37",
"      </a>",
"      ]. Further safety studies are needed before this approach can be recommended in infants.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/38/25189?source=see_link\">",
"       Polyethylene glycol",
"      </a>",
"      <strong>",
"       -electrolyte solution",
"      </strong>",
"      &mdash; 25",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour to a maximum of 1000",
"      <span class=\"nowrap\">",
"       mL/hr",
"      </span>",
"      by nasogastric tube until stool appears clear, or 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for four hours per day [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10,34\">",
"       10,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/28/20931?source=see_link\">",
"       Mineral oil",
"      </a>",
"      &mdash; 15 to 30 mL per year of age, up to 240 mL per day. In infants, neurologically impaired children, and others at high risk for gastroesophageal reflux, mineral oil should not be used because of risks of pneumonitis if the oil is aspirated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other agents that have been used successfully, but for which controlled trials are lacking, include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/59/29622?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/40\">",
"     40",
"    </a>",
"    ],",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34403?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/41\">",
"     41",
"    </a>",
"    ],",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/24/39299?source=see_link\">",
"     lactulose",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/42\">",
"     42",
"    </a>",
"    ],",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/1/42003?source=see_link\">",
"     senna",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/56/42883?source=see_link\">",
"     bisacodyl",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10191116\">",
"    <span class=\"h4\">",
"     Rectal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectal medications are more rapidly effective than oral medications for disimpaction, and may be a powerful motivator for toilet sitting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. In our practice, we prefer to use rectally administered medications rather than oral medications for severe impaction, because stimulants can cause intense discomfort and may not be effective in this setting. However, enemas are invasive and may be difficult to administer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Behavior modification'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    Phosphate sodium enemas or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/28/20931?source=see_link\">",
"     mineral oil",
"    </a>",
"    enemas followed by a phosphate enema may be used for rectal disimpaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. The doses are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Phosphate sodium enema",
"      </strong>",
"      &mdash; 1.13 ounces for children 2 to &lt;5 years; 2.25 ounces for children 5 to 12 years; 4.5 ounces for children &ge;12 years. These enemas are not to be used in children younger than two years of age. There are several case reports of life-threatening hyperphosphatasemia, particularly in young children, those with colonic dysmotility,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      with repeated administration of enemas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/43-46\">",
"       43-46",
"      </a>",
"      ]. Because these are small-volume enemas, the caregiver should be instructed to point the tip of the enema device toward the child's back after it is inserted, to direct the contents toward the bowel wall where it will be effective, rather than into the fecal mass.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/28/20931?source=see_link\">",
"       Mineral oil",
"      </a>",
"      <strong>",
"       enema",
"      </strong>",
"      &mdash; 2.25 ounces for children 2 to 12 years of age and 4.5 ounces for children &ge;12 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of soapsuds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], tap water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], magnesium (ie, Epsom salt) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/51-53\">",
"     51-53",
"    </a>",
"    ], and herbal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/5\">",
"     5",
"    </a>",
"    ] enemas is not recommended because of potential complications (colitis, water intoxication, bowel perforation, bowel necrosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/56/42883?source=see_link\">",
"     Bisacodyl",
"    </a>",
"    suppositories may be effective in older children, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/10/26787?source=see_link\">",
"     glycerin",
"    </a>",
"    suppositories may be effective in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10,54\">",
"     10,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10191125\">",
"    <span class=\"h4\">",
"     Oral and rectal",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach to disimpaction that combines oral and rectal medications (PEG without electrolytes and phosphate sodium enemas) is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef54749 \" href=\"mobipreview.htm?0/50/813\">",
"     table 3",
"    </a>",
"    ). &nbsp;An alternative combination approach consists of three to four consecutive three-day cycles in which a phosphate sodium enema is administered on day one, a",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/56/42883?source=see_link\">",
"     bisacodyl",
"    </a>",
"    suppository on day two, and bisacodyl tablet (10 mg) on day three [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4,24\">",
"     4,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3942228\">",
"    <span class=\"h3\">",
"     Maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;After disimpaction, a pattern of daily defecation should be maintained. The goal is to maintain soft bowel movements once or twice a day. Ensuring regularity is important because rectal impaction can recur, restarting the constipation cycle. Maintenance medications include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/38/25189?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    (PEG 3350 powder; Miralax&reg; and others),",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/28/20931?source=see_link\">",
"     mineral oil",
"    </a>",
"    , milk of magnesia, and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/24/39299?source=see_link\">",
"     lactulose",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Laxatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials give some support to the use of osmotic laxatives to improve stool frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    consistency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/55-58\">",
"     55-58",
"    </a>",
"    ], although a literature review concluded that the evidence base underlying this practice is weak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/59\">",
"     59",
"    </a>",
"    ]. Aggressive treatment is appropriate; early intervention appears to lead to more rapid recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/27\">",
"     27",
"    </a>",
"    ]. There is no evidence that tolerance develops to osmotic laxatives, and very little evidence that this is a problem for stimulant laxatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The laxatives that are considered safe and are used most often for infants and children include",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/38/25189?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/59/29622?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/24/39299?source=see_link\">",
"     lactulose",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/28/20931?source=see_link\">",
"     mineral oil",
"    </a>",
"    . The type of laxative is not as important as using an adequate dose and ensuring compliance; the choice should be individualized according to circumstances, familiarity, and the child's acceptance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/16,27\">",
"     16,27",
"    </a>",
"    ]. The dose should be based upon age, body weight, and severity of constipation (",
"    <a class=\"graphic graphic_table graphicRef63381 \" href=\"mobipreview.htm?5/56/6029\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Parents should be advised to adjust the laxative dose according to the response, and to increase the dose every two days until the child has one or two soft stools each day, or to decrease it if the patient develops diarrhea. Parents should be warned that some leaking or soiling may continue at first, especially if the child fears or continues to resist having a bowel movement.",
"   </p>",
"   <p>",
"    After two to four weeks, parents should be advised to encourage the child to use the bathroom for 5 to 10 minutes at the same time each day, preferably after breakfast or dinner. If the child fails to have a bowel movement for several days, it may be necessary to use an enema to empty the rectum, and then increase the laxative dose. If soiling recurs, disimpaction, as described above, may be necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Behavior modification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10191134\">",
"    <span class=\"h4\">",
"     Polyethylene glycol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/38/25189?source=see_link\">",
"     Polyethylene glycol",
"    </a>",
"    without electrolytes (PEG 3350, Miralax&reg;) is an osmotic laxative. It is approved for short-term management of constipation in adults, and is available without prescription in the United States. Experience in children is increasing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/2,3,61-67\">",
"     2,3,61-67",
"    </a>",
"    ]. Because it is more palatable and has fewer adverse effects than other agents, PEG without electrolytes has become the preferred laxative for children in many centers, even though it is not yet labeled for this use. The typical dose is 0.4 to 0.8",
"    <span class=\"nowrap\">",
"     gm/kg",
"    </span>",
"    per day (up to 17 gm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/61,62,64,68\">",
"     61,62,64,68",
"    </a>",
"    ]. In a dose-ranging trial, the dose of 0.4",
"    <span class=\"nowrap\">",
"     g/kg/day",
"    </span>",
"    was most likely to give high success rates (74 percent) while generating fewer complaints of abdominal pain or fecal incontinence than higher doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/69\">",
"     69",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    We recommend an initial dose of 4 tsp (17 gm = approximately 3.5 tsp), increased or decreased by",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    tsp to 1 tsp every other day until the consistency of the stools is soft to loose. We have rarely had to use more than 6 to 7 tsp per day.",
"    <br/>",
"    <br/>",
"    Initial experience suggests that PEG without electrolytes has efficacy greater than or similar to that of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/24/39299?source=see_link\">",
"     lactulose",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/59/29622?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    with fewer adverse effects and greater acceptance, as illustrated below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/58,61,65,66,70\">",
"     58,61,65,66,70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest controlled trials compared PEG without electrolytes (4 to 8 g per day) to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/24/39299?source=see_link\">",
"       lactulose",
"      </a>",
"      (3.3 to 6.7 g per day) in 96 children (aged 6 months to 3 years) with functional constipation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/66\">",
"       66",
"      </a>",
"      ]. At the end of 6 and 12 weeks of therapy, stool frequency was similar in both groups. However, compared to the children in the lactulose group, those in the PEG group had fewer hard stools (9 versus 34 percent and 6 versus 28 percent at 6 and 12 weeks, respectively), fewer episodes of fecal impaction (2 versus 13 percent during the 12 weeks), and less use of enemas (30 versus 43 percent and 17 versus 41 percent during the first and second six week periods, respectively). Children in the PEG group also had less vomiting and flatulence than did those treated with lactulose.",
"     </li>",
"     <li>",
"      In another controlled trial, 79 children with chronic constipation and fecal incontinence were randomly assigned to treatment with PEG without electrolytes or milk of magnesia for 12 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/70\">",
"       70",
"      </a>",
"      ]. Significant improvement in frequency of bowel movements, episodes of incontinence, and resolution of abdominal pain occurred in both groups. However, compliance was higher in the PEG group (95 versus 65 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral preparations of PEG with electrolytes (Transipeg&reg;, Movicol) are available outside the United States. The addition of electrolytes alters the taste, which may decrease palatability. One trial from the Netherlands compared the efficacy of PEG with electrolytes (Transipeg&reg;) to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/24/39299?source=see_link\">",
"     lactulose",
"    </a>",
"    in 100 children with functional constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/71\">",
"     71",
"    </a>",
"    ]. Compared to the pretreatment period, defecation frequency increased, and episodes of fecal incontinence decreased in both groups after eight weeks of therapy. However, success (defined as &ge;3 bowel movements per week and &le;1 episode of fecal incontinence every two weeks) occurred more frequently in the PEG group (56 versus 29 percent). Children in the PEG group reported less abdominal pain, straining, and pain at defecation, but complained of bad taste more often than those in the lactulose group. Similar results were reported in a smaller study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10191176\">",
"    <span class=\"h4\">",
"     Mineral oil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/28/20931?source=see_link\">",
"     Mineral oil",
"    </a>",
"    is a lubricant laxative that once was the mainstay of therapy for chronic constipation and fecal incontinence. It has largely been replaced by osmotic laxatives. Although there is a theoretic concern that chronic use of mineral oil may interfere with the absorption of fat soluble vitamins, this effect can be minimized by administering it in the mid-afternoon and at bedtime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/11,26,72\">",
"     11,26,72",
"    </a>",
"    ]. In addition, some providers prescribe a daily multivitamin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Mineral oil, particularly in large amounts, may not be palatable in children. It may be more palatable if served chilled and mixed in a 1:1 ratio with a fat-containing food that the child likes (eg, pudding, yogurt, chocolate syrup) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4\">",
"     4",
"    </a>",
"    ]. Families should be warned about the possibility of anal leakage of mineral oil, which may stain clothing or furniture.",
"    <br/>",
"    <br/>",
"    In one randomized trial in 37 children (3 to 13 years) with chronic functional constipation, mineral oil compared favorably to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/1/42003?source=see_link\">",
"     senna",
"    </a>",
"    concentrate (a stimulant laxative) in symptom control, frequency of recurrence, and duration of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/73\">",
"     73",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Because of the risk for aspiration, mineral oil should not be used in infants (&lt;12 months of age), or in children with neurodevelopmental abnormalities or gastroesophageal reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10191197\">",
"    <span class=\"h4\">",
"     Milk of magnesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Milk of magnesia (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/59/29622?source=see_link\">",
"     magnesium hydroxide",
"    </a>",
"    ) is an osmotic laxative that has a long history of success. It releases cholecystokinin, which stimulates gastrointestinal motility and secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ]. Magnesium hydroxide should be used with caution in infants since they are susceptible to hypermagnesemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/74-77\">",
"     74-77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10191204\">",
"    <span class=\"h4\">",
"     Lactulose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/24/39299?source=see_link\">",
"     Lactulose",
"    </a>",
"    is an osmotic laxative and is usually well tolerated in the long-term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ]. Lactulose is not absorbed by the small intestine. Side effects include flatulence and abdominal cramps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10191211\">",
"    <span class=\"h4\">",
"     Stimulant laxatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulant laxatives, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/1/42003?source=see_link\">",
"     senna",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/56/42883?source=see_link\">",
"     bisacodyl",
"    </a>",
"    , are sometimes used for brief periods to avoid recurrence of impaction (\"rescue\" therapy), and their use for this purpose is supported by clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ]. Controlled trials on the use of these agents for constipation in children are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/78\">",
"     78",
"    </a>",
"    ]. Traditionally, concerns were raised about the possible development of tolerance or physical dependence with chronic use of stimulant laxatives. The issue has not been systematically studied in humans, but it appears that tolerance is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/60\">",
"     60",
"    </a>",
"    ]. Nonetheless, most pediatric providers reserve stimulant laxatives for patients with severe constipation who do not respond to osmotic laxatives and dietary changes, preferably under supervision from a pediatric gastroenterologist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/79\">",
"     79",
"    </a>",
"    ]. These laxatives are often used in conjunction with a stool softener or lubricant such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/28/20931?source=see_link\">",
"     mineral oil",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3942235\">",
"    <span class=\"h4\">",
"     Newer pharmacological agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/28/38339?source=see_link\">",
"     Lubiprostone",
"    </a>",
"    (Amitiza) is an oral bicyclical fatty acid that selectively activates type 2 chloride channels in the apical membrane of the intestinal epithelial cells, hence stimulating chloride secretion, along with passive secretion of sodium and water, inducing peristalsis without stimulating gastrointestinal smooth muscle. Lubiprostone is used in adults for the treatment of chronic idiopathic constipation at a dose of 24 &micro;g twice daily, and for adult women with constipating-type irritable bowel syndrome at a lower dose. Several trials in adults have shown it to be effective for constipation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=see_link&amp;anchor=H30891009#H30891009\">",
"     \"Management of chronic constipation in adults\", section on 'Lubiprostone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other agents under investigation in adults include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/17/20755?source=see_link\">",
"     linaclotide",
"    </a>",
"    , a guanylate cyclase receptor agonist that also works on the intestinal enterocyte to stimulate chloride and fluid secretion, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/10/18596?source=see_link\">",
"     prucalopride",
"    </a>",
"    , a selective agonist 5-hydroxytryptamine-4 (5-HT4) receptor, leading to increased colonic motility and transit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=see_link\">",
"     \"Management of chronic constipation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Behavior modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavior modification is used to recondition the child to normal bowel habits. The typical behavior modification program for chronic constipation includes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parental supervision and encouragement of regular sitting on the toilet after meals (ie, for 5 to 10 minutes, two to three times per day) within 30 minutes of each meal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/12\">",
"       12",
"      </a>",
"      ]. Toilet sitting episodes should occur at the same time each day and be timed with a timer or stopwatch [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/80\">",
"       80",
"      </a>",
"      ]. The routine should be followed every day, particularly during times of transition (eg, holidays, vacations, or weekends) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4\">",
"       4",
"      </a>",
"      ]. For children whose feet do not touch the floor sitting on a regular toilet seat, it is helpful to use a stool for foot support. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2710?source=see_link&amp;anchor=H4#H4\">",
"       \"Prevention and treatment of acute constipation in infants and children\", section on 'Toilet training'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A reward system that is tailored to the child [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4,81\">",
"       4,81",
"      </a>",
"      ] and in which the reward is provided for effort (ie, toilet sitting) rather than success (ie, evacuation in the toilet) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/17,82,83\">",
"       17,82,83",
"      </a>",
"      ]. Rewards for preschoolers may include stickers or small sweets, reading books or singing songs while sitting, or special toys that are only used during toilet sitting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4\">",
"       4",
"      </a>",
"      ]. Rewards for school-aged children may include reading books together, activity books or hand-held computer games that are only used during sitting time, or coins that can be redeemed for small drug-store items [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Use of a diary to record bowel movements, the use of medication, and episodes of fecal incontinence, abdominal pain, and wetting. A sample of such a diary and a blank one that can be printed out for use by patients are shown in the following figures (",
"      <a class=\"graphic graphic_figure graphicRef62849 graphicRef53073 \" href=\"mobipreview.htm?17/35/17973\">",
"       figure 2A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Dyssynergic defecation, defined by the incomplete evacuation of fecal material from the rectum due to paradoxical contraction or failure to relax pelvic floor muscles when straining to defecate, is believed to be a functional disorder because there are no associated morphological or neurological abnormalities. Patients with dyssynergic defecation are candidates for biofeedback therapy, a form of behavior modification in which patients are taught how to relax pelvic floor muscles when defecating, by converting measurements of anal pressure or electromyographic activity into a simple visual or auditory signal. Although studies in children have not shown any benefit of biofeedback over laxatives alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/84,85\">",
"       84,85",
"      </a>",
"      ], it has been used with more success in adults with constipation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/86\">",
"       86",
"      </a>",
"      ]. For selected older children and adolescents with strong motivation and ability to maintain sustained attention, biofeedback therapy may be considered. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=see_link&amp;anchor=H30890995#H30890995\">",
"       \"Management of chronic constipation in adults\", section on 'Biofeedback'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dietary changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the treatment of fecal incontinence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic constipation, it is important to ingest a diet that is conducive to fecal regularity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. Increased intake of fruit and raw vegetables, bran, and whole-grain breads and cereals is commonly recommended, as is adequate intake of fluids other than milk, but evidence supporting these interventions is weak.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Fiber",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently inadequate evidence to support a general recommendation for fiber supplementation in children with constipation that is severe enough to come to medical attention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ]. A balanced diet that includes whole grains, fruits, and vegetables should be encouraged as a component of the treatment of constipation in children, but dietary changes should not be forced, nor should they replace the other interventions described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some observations suggest that increasing dietary fiber may be helpful in selected clinical situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. The consumption of high-fiber foods, which add bulk and hold more water in the stool, makes the stool softer and easier to release. However, the increased stool bulk may cause greater distension of the rectum and colon in children with a history of fecal retention. In such children, extra fiber intake should be encouraged only after colorectal tone has been restored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adequate intake of fiber may be particularly important during the time that laxative therapy is discontinued, when the increased stool bulk may raise the child's awareness of the need to evacuate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/5\">",
"     5",
"    </a>",
"    ]. Supplementation with glucomannan was a useful adjunct to disimpaction and behavioral interventions in a small randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/90\">",
"     90",
"    </a>",
"    ]. If necessary, a variety of fiber products are available over the counter (",
"    <a class=\"graphic graphic_table graphicRef64009 \" href=\"mobipreview.htm?26/8/26763\">",
"     table 5",
"    </a>",
"    ). These include powdered fiber that can be mixed in juice (and frozen into popsicles), wafers, or tablets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fluid intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that constipation can be successfully treated by increasing fluid intake unless the patient is clinically dehydrated. To ensure adequate hydration, children with chronic constipation or fecal incontinence should be encouraged to consume at least 32 to 64 ounces (960 to 1920 mL) of water or other non-milk liquids per day, particularly if they are using fiber supplements.",
"   </p>",
"   <p>",
"    Whether increasing fluids beyond the usual intake affects constipation is unclear. In one study, 108 prepubertal children (2 to 12 years of age) with moderate to severe simple constipation were randomly assigned to one of three groups: one was instructed to increase daily water intake by 50 percent; the second was asked to ingest additional hyperosmolar liquids such as juices; and the third to make no changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/91\">",
"     91",
"    </a>",
"    ]. There were no changes regarding stool frequency, consistency, or ease of defecation with either intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1989137\">",
"    <span class=\"h3\">",
"     Cow's milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intolerance to cow's milk, particularly in children with atopy, has been associated with chronic constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. In one double-blind crossover study in 65 constipated children who were refractory to laxative therapy, 68 percent of children improved while receiving soy milk compared to cow's milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/92\">",
"     92",
"    </a>",
"    ]. Constipation recurred within days of reintroduction of cow's milk. Another study suggested that constipation can be a delayed clinical manifestation of cows' milk protein intolerance, particularly in children with a personal or family history of atopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/94\">",
"     94",
"    </a>",
"    ]. Studies disagree regarding whether bowel habits improve when cow's milk is eliminated from the diets of children with constipation, with or without a history of cow's milk protein sensitivity or atopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/15,95,96\">",
"     15,95,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A one- to two-week trial of elimination of cow's milk protein from the diet should be considered in atopic children whose constipation is unresponsive to other measures to exclude cow's milk protein intolerance as the cause of constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10,15,95\">",
"     10,15,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3942250\">",
"    <span class=\"h3\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics, defined as live microorganisms which when administered in adequate amounts confer a health benefit on the host, are increasingly being used in the management of constipation in adults and children. The most widely studied organisms are within the genera",
"    <em>",
"     Bifidobacterium",
"    </em>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/5/1108?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16554?source=see_link&amp;anchor=H700205307#H700205307\">",
"     \"Probiotics for gastrointestinal diseases\", section on 'Constipation'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The hypothesis that probiotics may have therapeutic potential for the treatment of constipation is supported by data demonstrating differences in the intestinal microbiota between healthy individuals and patients with chronic constipation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/97\">",
"     97",
"    </a>",
"    ]. Administration of Bifidobacterium has also been shown to improve colonic transit times in constipated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/98\">",
"     98",
"    </a>",
"    ]. To date, however, the only three RCTs that have addressed the use of probiotics in the treatment of constipation in children have had conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 84 children were randomized to",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/24/39299?source=see_link\">",
"       lactulose",
"      </a>",
"      plus",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/5/1108?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      <em>",
"       rhamnosus GG",
"      </em>",
"      or a lactulose-containing placebo for 12 weeks. There were no differences between the experimental and control groups in terms of spontaneous bowel movements or fecal soiling at 12 or 24 weeks of follow up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another smaller RCT found a significantly higher defecation frequency in patients receiving",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/5/1108?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      <em>",
"       casei rhamnosus Lcr35",
"      </em>",
"      (n = 18) compared with placebo (n = 9), but no difference when compared with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/5/5205?source=see_link\">",
"       magnesium oxide",
"      </a>",
"      (n = 18) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a trial, infants with chronic constipation randomly assigned to receive",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/5/1108?source=see_link\">",
"       Lactobacillus",
"      </a>",
"      <em>",
"       reuteri",
"      </em>",
"      (DSM 17938) had a significantly higher frequency of bowel movements than infants receiving placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/101\">",
"       101",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the use of probiotics for constipation appears promising, the evidence available from controlled trials in children and adults is currently insufficient to draw any general conclusions, let alone identify the most effective strain, dose, or treatment duration. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of chronic constipation requires monitoring by the clinician or clinician's staff to prevent recurrences. In the first days of treatment, especially if disimpaction was warranted, phone follow-up is critical. The child may need to return to the office if he or she is still passing hard stools. Patients who require disimpaction should be seen soon after disimpaction to review the details of maintenance therapy.",
"   </p>",
"   <p>",
"    After disimpaction or in patients who did not require disimpaction, progress should be evaluated initially on a monthly basis and then less frequently (eg, every three to four months) by checking the child's stool records (",
"    <a class=\"graphic graphic_figure graphicRef62849 graphicRef53073 \" href=\"mobipreview.htm?17/35/17973\">",
"     figure 2A-B",
"    </a>",
"    ) and repeating the abdominal and rectal examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/16,102\">",
"     16,102",
"    </a>",
"    ]. The follow-up visits provide opportunities to evaluate progress, adjust medication regimens, anticipate challenges, and celebrate successes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4\">",
"     4",
"    </a>",
"    ]. As laxative therapy is gradually discontinued, the importance of dietary and behavioral interventions can be reinforced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure of treatment, manifested by continued soiling and recurrent impaction, suggests the need to review education and other treatment components. Most treatment failures are caused by inadequate medication or premature discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/5\">",
"     5",
"    </a>",
"    ]. Poor compliance with the treatment program is another important cause of treatment failure. In some children, compliance may be impaired by behavior problems (eg, oppositional behavior, poor attention span, high activity level) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/16,24,103\">",
"     16,24,103",
"    </a>",
"    ]. Such patients and their families may benefit from group therapy and a more rigorous behavioral approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeated failure despite adequate compliance requires reconsideration of the diagnosis and the possibility of further testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=see_link\">",
"     \"Constipation in children: Etiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DISCONTINUATION OF LAXATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of therapy is to achieve one daily bowel movement without fecal incontinence. In many cases, laxatives need to be taken for months and sometimes years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/6,105\">",
"     6,105",
"    </a>",
"    ] to induce daily soft stools [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/102\">",
"     102",
"    </a>",
"    ]. Once the child has achieved regular bowel habits (and independently uses the toilet), the frequency of mandatory toilet sitting and the use of laxatives can be reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/16\">",
"     16",
"    </a>",
"    ]. The laxative dose is gradually decreased to a dose that will prevent soiling, and maintain one to two bowel movements per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further reduction or discontinuation of laxative treatment may be considered after an additional six months of stability, but some children require ongoing laxative treatment for one or more years. Parents must be warned not to stop the laxative without consulting the child's clinician. Stopping laxatives too soon will lead to a prompt recurrence and disrupt the treatment program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As laxative therapy is discontinued, it is particularly important to encourage compliance with the behavioral and dietary regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/82\">",
"     82",
"    </a>",
"    ]. In addition, the parents and child should have a \"rescue\" plan if the child goes more than three days without a stool or has other indications of recurrence (ie, hard stools, abdominal pain, smears in the underwear) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4\">",
"     4",
"    </a>",
"    ]. The rescue plan may involve the use of an enema or suppository followed by an increase in the laxative dose. The development of such a plan empowers the child and family to anticipate, tolerate, and treat recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT OF NONRETENTIVE FECAL INCONTINENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-retentive fecal incontinence is the term used to describe fecal incontinence that occurs in the absence of constipation or other organic disease. Children with this disorder usually have full bowel movements in their clothing rather than just soiling. Treatment requires an approach similar to that described above but without laxative therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No widely effective treatments have been established, but most approaches focus on behavior modification and psychosocial diagnosis and support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/19\">",
"     19",
"    </a>",
"    ]. The behavioral protocol generally includes a highly structured toilet training protocol designed to encourage frequent and sustained efforts at defecation and supported by behavior modification techniques including a reward system. Biofeedback and laxatives are not helpful in these children (provided that constipation has been carefully excluded) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only one study has reported long-term outcomes in patients with non-retentive fecal incontinence, and this suggested very slow resolution of the problem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/107\">",
"     107",
"    </a>",
"    ]. Among children who had intensive medical and behavioral treatment for two years, only 29 percent had resolved after two years of treatment, 65 percent after five years, and about 90 percent after 10 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consultation with a pediatric gastroenterologist should be considered in children in whom oral or rectal medications are ineffective for disimpaction and in whom dietary changes and laxative therapy are ineffective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"     10",
"    </a>",
"    ]. Additional evaluation before consultation should include T4, TSH, calcium, celiac disease antibodies, and lead. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=see_link\">",
"     \"Constipation in children: Etiology and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Anal sphincter release",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some children with constipation refractory to medical therapy may respond to an intervention to release the internal anal sphincter through myectomy or injection of botulinum toxin. These children may have internal anal sphincter (IAS) achalasia, which also has been termed ultra-short segment Hirschsprung disease. The disorder is identified by a lack of recto-anal inhibitory reflex on anal manometry. No randomized controlled trials have compared these approaches to medical and behavioral treatment, so there is little information to guide selection of patients for surgical approaches.",
"   </p>",
"   <p>",
"    Patients with IAS achalasia diagnosed on anorectal manometry tend to respond well to anal sphincter release. In a case series of 15 such children, surgical myectomy had a high success rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/108\">",
"     108",
"    </a>",
"    ]. A series of similar patients treated with botulinum toxin injection to the internal anal sphincter yielded similar results, although the duration of the effect varied from a few weeks to a few months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interestingly, patients without demonstrable abnormalities on anorectal manometry also may respond to sphincter release. A double-blind randomized trial in 42 children with idiopathic chronic constipation unresponsive to laxative treatment compared myectomy to botulinum toxin treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/110\">",
"     110",
"    </a>",
"    ]. All of these patients had normal findings on anorectal manometry, with no evidence of IAS. Myectomy and botulinum toxin yielded improvement in symptom severity score in 55 and 80 percent of patients, respectively. Thus, both groups showed improvement, but the symptom severity score and other measures of constipation were not significantly different between the two treatment groups.",
"   </p>",
"   <p>",
"    Myectomy can lead to incontinence. Therefore, we use myectomy only in selected patients with clear IAS achalasia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a good response to a trial of botulinum toxin treatment. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rare patient with intractable constipation and normal anorectal manometry (or one who fails to respond to botulinum toxin injection) may be considered for other surgical procedures, including antegrade continence enema (ACE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/111-114\">",
"     111-114",
"    </a>",
"    ], primary intestinal diversion (ileostomy or colostomy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/111,115\">",
"     111,115",
"    </a>",
"    ], or colonic resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/111,116,117\">",
"     111,116,117",
"    </a>",
"    ]. ACE provides a conduit for daily colonic irrigation, and is also used for patients with myelomeningocele and bowel dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26344?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the management of myelomeningocele (spina bifida)\", section on 'Bowel management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective series of 44 patients reported the following outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/111\">",
"     111",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary diversion procedures had satisfactory outcomes in 95 percent of patients, and intestinal continuity was reestablished in 74 percent at a mean of 27 months post diversion. Those with colonic dysmotility as documented by manometry underwent resection of the dysfunctional segment at the time of reanastomosis.",
"     </li>",
"     <li>",
"      ACE had a satisfactory outcome in 63 percent of patients. These patients generally required ongoing ACE treatment throughout the follow up period, but displayed some improvement in colonic motility after one year of treatment.",
"     </li>",
"     <li>",
"      Primary colonic resection yielded satisfactory outcome in only 22 percent of patients, either because of persistent constipation or fecal incontinence. 44 percent of patients required a second surgical procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on this and other anecdotal reports, we feel that primary colonic resection should not be offered as a treatment for chronic constipation. Rarely, primary diversion via colostomy or ileostomy with subsequent resection and re-anastomosis, and ACE procedures may be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement can be expected in virtually all patients who cooperate with the type of comprehensive approach described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/8,15,80,118,119\">",
"     8,15,80,118,119",
"    </a>",
"    ]. On the other hand, complete recovery, defined as three or more bowel movements weekly with no or minimal soiling while off laxatives, is seen less often [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/15,16,18,120\">",
"     15,16,18,120",
"    </a>",
"    ]. A systematic review was unable to identify factors that predict which patients would fail to respond to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recovery rates increase significantly over time; they are approximately 30 to 50 percent after one year, and 48 to 75 percent after five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/15,18,119,122\">",
"     15,18,119,122",
"    </a>",
"    ]. As an example, a follow-up evaluation of 97 patients treated in an encopresis clinic showed that 43 percent of a total of 97 patients (all of whom had been treated with milk of magnesia, a high-fiber diet, and bowel-training techniques) recovered by one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/122\">",
"     122",
"    </a>",
"    ]. Severe constipation, abnormal contraction of the external sphincter and pelvic floor during attempted defecation, and inability to defecate a water-filled 100 mL rectal balloon in one minute or less were significantly related to treatment failure.",
"   </p>",
"   <p>",
"    Recovery rates are higher in populations in primary care practices, presumably because this population includes children with less severe or refractory constipation as compared to children referred for specialty care. In a retrospective review of children younger than two years of age who were treated for acute or chronic constipation in a general pediatrics clinic, the following results were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/123\">",
"     123",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      116 children were initially treated with dietary changes, corn syrup, or both; among the 108 who returned for follow-up, constipation had resolved in 25 percent.",
"     </li>",
"     <li>",
"      100 children were treated with laxatives (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/59/29622?source=see_link\">",
"       magnesium hydroxide",
"      </a>",
"      or PEG without electrolytes); 44 of these had failed dietary interventions, corn syrup, or both; of the 93 patients who returned for follow-up, laxative therapy was successful (defined as resolution of all symptoms of constipation) in 92 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most children with functional constipation will have good clinical outcomes in adulthood if they are adequately treated during childhood. In a study of 401 children treated with a six- to eight-week treatment protocol in the Netherlands, and followed for a median of 11 years, 25 percent still had symptoms as adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/124\">",
"     124",
"    </a>",
"    ]. Risk factors for lack of long-term recovery included older age at onset, longer delay before referral to a pediatric gastroenterologist, and fewer bowel movements per week at presentation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/2/43041?source=see_link\">",
"       \"Patient information: Constipation in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/59/27570?source=see_link\">",
"       \"Patient information: Fecal incontinence in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/7/15477?source=see_link\">",
"       \"Patient information: Constipation in infants and children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of chronic functional constipation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fecal incontinence requires a comprehensive approach that includes education of the parent and child, pharmacotherapy, a program of regular toileting, dietary changes, and frequent, close follow-up. The goal of therapy is the achievement of one soft stool per day. Improvement can be expected in the majority of such patients, although it may be gradual.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The North American Society of Pediatric Gastroenterology, Hepatology and Nutrition's (NASPGHAN) medical position statement on constipation summarizes the approach to constipation as follows [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Provide parental education.",
"     </li>",
"     <li>",
"      Determine whether impaction is present.",
"     </li>",
"     <li>",
"      Remove the impaction via oral or rectal medication.",
"     </li>",
"     <li>",
"      Start maintenance therapy with laxatives, behavior modification, and dietary changes; adjust laxatives as necessary.",
"     </li>",
"     <li>",
"      Provide close follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of infants may include non-digestible osmotically active carbohydrates, with osmotic laxatives",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      occasional glycerine suppositories if necessary.",
"     </li>",
"     <li>",
"      We recommend NOT using",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/28/20931?source=see_link\">",
"       mineral oil",
"      </a>",
"      , enemas, and stimulant laxatives in infants, due to safety concerns (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment of infants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest treating children with chronic constipation with a combination of daily laxatives and behavior modification rather than either therapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disimpaction can usually be accomplished in the outpatient setting with oral medications, rectal medications, or a combination. Oral medications are generally effective when given in appropriate doses. These are the treatment of choice for children with mild and moderate chronic constipation, particularly in children with a history of painful defecation, or perineal trauma. Enemas or brief hospitalization for disimpaction may be necessary for children with severe constipation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Disimpaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After disimpaction, we recommend titrating the dose of laxatives to achieve about one soft stool daily (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The choice of laxative is less important than using an adequate dose and assuring compliance. The dose should be based upon age, body weight, and severity of constipation (",
"      <a class=\"graphic graphic_table graphicRef63381 \" href=\"mobipreview.htm?5/56/6029\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laxatives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest use of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/38/25189?source=see_link\">",
"       Polyethylene glycol",
"      </a>",
"      (PEG), as the initial choice for maintenance therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This drug is safe and effective, and is usually better accepted by children than other laxatives. High doses of PEG also may be effective for initial disimpaction of children with mild-moderate constipation. (See",
"      <a class=\"local\" href=\"#H10191134\">",
"       'Polyethylene glycol'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Disimpaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The parents and child should have a \"rescue\" plan if the child goes more than three days without a stool or has other indications of recurrence (ie, hard stools, abdominal pain, smears in the underwear). The rescue plan may involve administration of a stimulant laxative, enema or suppository followed by an increased laxative dose. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laxatives'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of a behavior modification scheme to support regular toileting habits and encourage a child's cooperation is an important part of treatment for functional constipation. Components include toilet-sitting after meals under the supervision and encouragement of a caregiver, a reward system to enhance the child's cooperation, and keeping a record of stooling. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Behavior modification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regular and frequent follow-up is necessary to reinforce the need for continuation of laxative therapy, toilet sitting, and dietary changes. The laxative dose can be titrated and the rescue plan reviewed at follow-up visits. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the child has achieved regular bowel habits, the frequency of toilet sitting and laxative use can be reduced. We typically wait until optimal bowel habits are achieved and stable for at least six months before laxative use is further decreased. Some children require ongoing laxative treatment for one or more years. Behavioral and dietary interventions increase in importance as laxative therapy is discontinued. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Discontinuation of laxatives'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Non-retentive fecal incontinence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of children with functional non-retentive fecal incontinence (encopresis without evidence of constipation) is similar, but laxatives are not used. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment of nonretentive fecal incontinence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/1\">",
"      Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 Suppl 2:II43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/2\">",
"      Michail S, Gendy E, Preud'Homme D, Mezoff A. Polyethylene glycol for constipation in children younger than eighteen months old. J Pediatr Gastroenterol Nutr 2004; 39:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/3\">",
"      Loening-Baucke V, Krishna R, Pashankar DS. Polyethylene glycol 3350 without electrolytes for the treatment of functional constipation in infants and toddlers. J Pediatr Gastroenterol Nutr 2004; 39:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/4\">",
"      Schonwald A, Rappaport L. Consultation with the specialist: encopresis: assessment and management. Pediatr Rev 2004; 25:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/5\">",
"      Abi-Hanna A, Lake AM. Constipation and encopresis in childhood. Pediatr Rev 1998; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/6\">",
"      Loening-Baucke V. Chronic constipation in children. Gastroenterology 1993; 105:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/7\">",
"      Felt B, Wise CG, Olson A, et al. Guideline for the management of pediatric idiopathic constipation and soiling. Multidisciplinary team from the University of Michigan Medical Center in Ann Arbor. Arch Pediatr Adolesc Med 1999; 153:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/8\">",
"      Loening-Baucke V. Clinical approach to fecal soiling in children. Clin Pediatr (Phila) 2000; 39:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/9\">",
"      Brazzelli M, Griffiths PV, Cody JD, Tappin D. Behavioural and cognitive interventions with or without other treatments for the management of faecal incontinence in children. Cochrane Database Syst Rev 2011; :CD002240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/10\">",
"      Constipation Guideline Committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Evaluation and treatment of constipation in infants and children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2006; 43:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/11\">",
"      DAVIDSON M, KUGLER MM, BAUER CH. Diagnosis and management in children with severe and protracted constipation and obstipation. J Pediatr 1963; 62:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/12\">",
"      Nolan T, Debelle G, Oberklaid F, Coffey C. Randomised trial of laxatives in treatment of childhood encopresis. Lancet 1991; 338:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/13\">",
"      Borowitz SM, Cox DJ, Sutphen JL, Kovatchev B. Treatment of childhood encopresis: a randomized trial comparing three treatment protocols. J Pediatr Gastroenterol Nutr 2002; 34:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/14\">",
"      Berg I, Forsythe I, Holt P, Watts J. A controlled trial of 'Senokot' in faecal soiling treated by behavioural methods. J Child Psychol Psychiatry 1983; 24:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/15\">",
"      Loening-Baucke V. Controversies in the management of chronic constipation. J Pediatr Gastroenterol Nutr 2001; 32 Suppl 1:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/16\">",
"      Loening-Baucke V. Encopresis. Curr Opin Pediatr 2002; 14:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/17\">",
"      Youssef NN, Di Lorenzo C. Childhood constipation: evaluation and treatment. J Clin Gastroenterol 2001; 33:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/18\">",
"      Staiano A, Andreotti MR, Greco L, et al. Long-term follow-up of children with chronic idiopathic constipation. Dig Dis Sci 1994; 39:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/19\">",
"      Benninga MA, Taminiau JA. Diagnosis and treatment efficacy of functional non-retentive fecal soiling in childhood. J Pediatr Gastroenterol Nutr 2001; 32 Suppl 1:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/20\">",
"      van Ginkel R, Reitsma JB, B&uuml;ller HA, et al. Childhood constipation: longitudinal follow-up beyond puberty. Gastroenterology 2003; 125:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/21\">",
"      McGrath ML, Mellon MW, Murphy L. Empirically supported treatments in pediatric psychology: constipation and encopresis. J Pediatr Psychol 2000; 25:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/22\">",
"      Brooks RC, Copen RM, Cox DJ, et al. Review of the treatment literature for encopresis, functional constipation, and stool-toileting refusal. Ann Behav Med 2000; 22:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/23\">",
"      van Dijk M, Bongers ME, de Vries GJ, et al. Behavioral therapy for childhood constipation: a randomized, controlled trial. Pediatrics 2008; 121:e1334.",
"     </a>",
"    </li>",
"    <li>",
"     Rockney R. Encopresis. In: Developmental Behavioral Pediatrics, 3rd, Levine MD, Carey WB, Crocker AC (Eds), WB Saunders, Philadelphia 1999. p.413.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/25\">",
"      Levine MD. Encopresis: its potentiation, evaluation, and alleviation. Pediatr Clin North Am 1982; 29:315.",
"     </a>",
"    </li>",
"    <li>",
"     Croffie JMB, Fitzgerald JF. Idiopathic constipation. In: Pediatric Gastrointestinal Disease, 4th, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker Inc., Ontario 2004. p.1001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/27\">",
"      Borowitz SM, Cox DJ, Kovatchev B, et al. Treatment of childhood constipation by primary care physicians: efficacy and predictors of outcome. Pediatrics 2005; 115:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/28\">",
"      Gleghorn EE, Heyman MB, Rudolph CD. No-enema therapy for idiopathic constipation and encopresis. Clin Pediatr (Phila) 1991; 30:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/29\">",
"      Gilger MA, Wagner ML, Barrish JO, et al. New treatment for rectal impaction in children: an efficacy, comfort, and safety trial of the pulsed-irrigation enhanced-evacuation procedure. J Pediatr Gastroenterol Nutr 1994; 18:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/30\">",
"      Burke MS, Ragi JM, Karamanoukian HL, et al. New strategies in nonoperative management of meconium ileus. J Pediatr Surg 2002; 37:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/31\">",
"      Kao SC, Franken EA Jr. Nonoperative treatment of simple meconium ileus: a survey of the Society for Pediatric Radiology. Pediatr Radiol 1995; 25:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/32\">",
"      Wood BP, Katzberg RW. Tween 80/diatrizoate enemas in bowel obstruction. AJR Am J Roentgenol 1978; 130:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/33\">",
"      Tolia V, Lin CH, Elitsur Y. A prospective randomized study with mineral oil and oral lavage solution for treatment of faecal impaction in children. Aliment Pharmacol Ther 1993; 7:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/34\">",
"      Ingebo KB, Heyman MB. Polyethylene glycol-electrolyte solution for intestinal clearance in children with refractory encopresis. A safe and effective therapeutic program. Am J Dis Child 1988; 142:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/35\">",
"      Candy DC, Edwards D, Geraint M. Treatment of faecal impaction with polyethelene glycol plus electrolytes (PGE + E) followed by a double-blind comparison of PEG + E versus lactulose as maintenance therapy. J Pediatr Gastroenterol Nutr 2006; 43:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/36\">",
"      Youssef NN, Peters JM, Henderson W, et al. Dose response of PEG 3350 for the treatment of childhood fecal impaction. J Pediatr 2002; 141:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/37\">",
"      Bekkali NL, van den Berg MM, Dijkgraaf MG, et al. Rectal fecal impaction treatment in childhood constipation: enemas versus high doses oral PEG. Pediatrics 2009; 124:e1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/38\">",
"      Zanetti G, Marchiori E, Gasparetto TD, et al. Lipoid pneumonia in children following aspiration of mineral oil used in the treatment of constipation: high-resolution CT findings in 17 patients. Pediatr Radiol 2007; 37:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/39\">",
"      Bandla HP, Davis SH, Hopkins NE. Lipoid pneumonia: a silent complication of mineral oil aspiration. Pediatrics 1999; 103:E19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/40\">",
"      Loening-Baucke VA, Younoszai MK. Effect of treatment on rectal and sigmoid motility in chronically constipated children. Pediatrics 1984; 73:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/41\">",
"      Griffin GC, Roberts SD, Graham G. How to resolve stool retention in a child. Underwear soiling is not a behavior problem. Postgrad Med 1999; 105:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/42\">",
"      Halabi IM. Cisapride in management of chronic pediatric constipation. J Pediatr Gastroenterol Nutr 1999; 28:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/43\">",
"      Helikson MA, Parham WA, Tobias JD. Hypocalcemia and hyperphosphatemia after phosphate enema use in a child. J Pediatr Surg 1997; 32:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/44\">",
"      Biebl A, Grillenberger A, Schmitt K. Enema-induced severe hyperphosphatemia in children. Eur J Pediatr 2009; 168:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/45\">",
"      Mendoza J, Legido J, Rubio S, Gisbert JP. Systematic review: the adverse effects of sodium phosphate enema. Aliment Pharmacol Ther 2007; 26:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/46\">",
"      Ismail EA, Al-Mutairi G, Al-Anzy H. A fatal small dose of phosphate enema in a young child with no renal or gastrointestinal abnormality. J Pediatr Gastroenterol Nutr 2000; 30:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/47\">",
"      Orchard JL, Lawson R. Severe colitis induced by soap enemas. South Med J 1986; 79:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/48\">",
"      Pike BF, Phillippi PJ, Lawson EH Jr. Soap colitis. N Engl J Med 1971; 285:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/49\">",
"      ZISKIND A, GELLIS SS. Water intoxication following tap-water enemas. AMA J Dis Child 1958; 96:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/50\">",
"      Chertow GM, Brady HR. Hyponatraemia from tap-water enema. Lancet 1994; 344:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/51\">",
"      Ashton MR, Sutton D, Nielsen M. Severe magnesium toxicity after magnesium sulphate enema in a chronically constipated child. BMJ 1990; 300:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/52\">",
"      Brown AT, Campbell WA. Hazards of hypertonic magnesium enema therapy. Arch Dis Child 1978; 53:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/53\">",
"      Tofil NM, Benner KW, Winkler MK. Fatal hypermagnesemia caused by an Epsom salt enema: a case illustration. South Med J 2005; 98:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/54\">",
"      Weisman LE, Merenstein GB, Digirol M, et al. The effect of early meconium evacuation on early-onset hyperbilirubinemia. Am J Dis Child 1983; 137:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/55\">",
"      Hejl M, Kamper J, Ebbesen F, Hansted C. [Infantile constipation and Allomin-lactulose. Treatment of infantile obstipation in infants fed with breast milk substitutes. A controlled clinical trial of 2 per cent and 4 per cent Allomin-lactulose]. Ugeskr Laeger 1990; 152:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/56\">",
"      Pitzalis G, Deganello F, Mariani P, et al. [Lactitol in chronic idiopathic constipation in children]. Pediatr Med Chir 1995; 17:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/57\">",
"      Martino AM, Pesce F, Rosati U. [The effects of lactitol in the treatment of intestinal stasis in childhood]. Minerva Pediatr 1992; 44:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/58\">",
"      Gordon M, Naidoo K, Akobeng AK, Thomas AG. Osmotic and stimulant laxatives for the management of childhood constipation. Cochrane Database Syst Rev 2012; 7:CD009118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/59\">",
"      Pijpers MA, Tabbers MM, Benninga MA, Berger MY. Currently recommended treatments of childhood constipation are not evidence based: a systematic literature review on the effect of laxative treatment and dietary measures. Arch Dis Child 2009; 94:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/60\">",
"      M&uuml;ller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005; 100:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/61\">",
"      Loening-Baucke V. Polyethylene glycol without electrolytes for children with constipation and encopresis. J Pediatr Gastroenterol Nutr 2002; 34:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/62\">",
"      Pashankar DS, Bishop WP. Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children. J Pediatr 2001; 139:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/63\">",
"      Pashankar DS, Bishop WP, Loening-Baucke V. Long-term efficacy of polyethylene glycol 3350 for the treatment of chronic constipation in children with and without encopresis. Clin Pediatr (Phila) 2003; 42:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/64\">",
"      Pashankar DS, Loening-Baucke V, Bishop WP. Safety of polyethylene glycol 3350 for the treatment of chronic constipation in children. Arch Pediatr Adolesc Med 2003; 157:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/65\">",
"      Gremse DA, Hixon J, Crutchfield A. Comparison of polyethylene glycol 3350 and lactulose for treatment of chronic constipation in children. Clin Pediatr (Phila) 2002; 41:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/66\">",
"      Dupont C, Leluyer B, Maamri N, et al. Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children. J Pediatr Gastroenterol Nutr 2005; 41:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/67\">",
"      Thomson MA, Jenkins HR, Bisset WM, et al. Polyethylene glycol 3350 plus electrolytes for chronic constipation in children: a double blind, placebo controlled, crossover study. Arch Dis Child 2007; 92:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/68\">",
"      Dupont C, Leluyer B, Amar F, et al. A dose determination study of polyethylene glycol 4000 in constipated children: factors influencing the maintenance dose. J Pediatr Gastroenterol Nutr 2006; 42:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/69\">",
"      Nurko S, Youssef NN, Sabri M, et al. PEG3350 in the treatment of childhood constipation: a multicenter, double-blinded, placebo-controlled trial. J Pediatr 2008; 153:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/70\">",
"      Loening-Baucke V, Pashankar DS. A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence. Pediatrics 2006; 118:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/71\">",
"      Voskuijl W, de Lorijn F, Verwijs W, et al. PEG 3350 (Transipeg) versus lactulose in the treatment of childhood functional constipation: a double blind, randomised, controlled, multicentre trial. Gut 2004; 53:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/72\">",
"      Clark JH, Russell GJ, Fitzgerald JF, Nagamori KE. Serum beta-carotene, retinol, and alpha-tocopherol levels during mineral oil therapy for constipation. Am J Dis Child 1987; 141:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/73\">",
"      Sondheimer JM, Gervaise EP. Lubricant versus laxative in the treatment of chronic functional constipation of children: a comparative study. J Pediatr Gastroenterol Nutr 1982; 1:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/74\">",
"      Sullivan JE, Berman BW. The pediatric forum: hypermagnesemia with lethargy and hypotonia due to administration of magnesium hydroxide to a 4-week-old infant. Arch Pediatr Adolesc Med 2000; 154:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/75\">",
"      Mofenson HC, Caraccio TR. Magnesium intoxication in a neonate from oral magnesium hydroxide laxative. J Toxicol Clin Toxicol 1991; 29:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/76\">",
"      Alison LH, Bulugahapitiya D. Laxative induced magnesium poisoning in a 6 week old infant. BMJ 1990; 300:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/77\">",
"      Humphrey M, Kennon S, Pramanik AK. Hypermagnesemia from antacid administration in a newborn infant. J Pediatr 1981; 98:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/78\">",
"      Price KJ, Elliott TM. What is the role of stimulant laxatives in the management of childhood constipation and soiling?. Cochrane Database Syst Rev 2001; :CD002040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/79\">",
"      Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003; 349:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/80\">",
"      Levine MD, Bakow H. Children with encopresis: a study of treatment outcome. Pediatrics 1976; 58:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/81\">",
"      Howe AC, Walker CE. Behavioral management of toilet training, enuresis, and encopresis. Pediatr Clin North Am 1992; 39:413.",
"     </a>",
"    </li>",
"    <li>",
"     Belamarich PF. Constipation. In: Primary Pediatric Care, 4th, Hoekelman RA (Ed), Mosby, St. Louis 2001. p.1066.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/83\">",
"      Nolan T, Oberklaid F. New concepts in the management of encopresis. Pediatr Rev 1993; 14:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/84\">",
"      Loening-Baucke V. Biofeedback treatment for chronic constipation and encopresis in childhood: long-term outcome. Pediatrics 1995; 96:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/85\">",
"      van der Plas RN, Benninga MA, B&uuml;ller HA, et al. Biofeedback training in treatment of childhood constipation: a randomised controlled study. Lancet 1996; 348:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/86\">",
"      Rao SS. Biofeedback therapy for constipation in adults. Best Pract Res Clin Gastroenterol 2011; 25:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/87\">",
"      Chao HC, Lai MW, Kong MS, et al. Cutoff volume of dietary fiber to ameliorate constipation in children. J Pediatr 2008; 153:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/88\">",
"      Volta U, Vincentini O, Silano M, Collaborating Centers of the Italian Registry of Celiac Disease. Papillary cancer of thyroid in celiac disease. J Clin Gastroenterol 2011; 45:e44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/89\">",
"      Tabbers MM, Boluyt N, Berger MY, Benninga MA. Nonpharmacologic treatments for childhood constipation: systematic review. Pediatrics 2011; 128:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/90\">",
"      Loening-Baucke V, Miele E, Staiano A. Fiber (glucomannan) is beneficial in the treatment of childhood constipation. Pediatrics 2004; 113:e259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/91\">",
"      Young RJ, Beerman LE, Vanderhoof JA. Increasing oral fluids in chronic constipation in children. Gastroenterol Nurs 1998; 21:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/92\">",
"      Iacono G, Cavataio F, Montalto G, et al. Intolerance of cow's milk and chronic constipation in children. N Engl J Med 1998; 339:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/93\">",
"      Shah N, Lindley K, Milla P. Cow's milk and chronic constipation in children. N Engl J Med 1999; 340:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/94\">",
"      Carroccio A, Montalto G, Custro N, et al. Evidence of very delayed clinical reactions to cow's milk in cow's milk-intolerant patients. Allergy 2000; 55:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/95\">",
"      Irastorza I, Iba&ntilde;ez B, Delgado-Sanzonetti L, et al. Cow's-milk-free diet as a therapeutic option in childhood chronic constipation. J Pediatr Gastroenterol Nutr 2010; 51:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/96\">",
"      Daher S, Tahan S, Sol&eacute; D, et al. Cow's milk protein intolerance and chronic constipation in children. Pediatr Allergy Immunol 2001; 12:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/97\">",
"      Zoppi G, Cinquetti M, Luciano A, et al. The intestinal ecosystem in chronic functional constipation. Acta Paediatr 1998; 87:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/98\">",
"      Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009; 29:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/99\">",
"      Banaszkiewicz A, Szajewska H. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: a double-blind, placebo-controlled randomized trial. J Pediatr 2005; 146:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/100\">",
"      Bu LN, Chang MH, Ni YH, et al. Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation. Pediatr Int 2007; 49:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/101\">",
"      Coccorullo P, Strisciuglio C, Martinelli M, et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatr 2010; 157:598.",
"     </a>",
"    </li>",
"    <li>",
"     Loening-Baucke V. Constipation and encopresis. In: Pediatric Gastroenterology and Nutrition in Clinical Practice, Lifschitz CH (Ed), Marcel Dekker, New York 2001. p.551.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/103\">",
"      van Dijk M, Benninga MA, Grootenhuis MA, Last BF. Prevalence and associated clinical characteristics of behavior problems in constipated children. Pediatrics 2010; 125:e309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/104\">",
"      Stark LJ, Owens-Stively J, Spirito A, et al. Group behavioral treatment of retentive encopresis. J Pediatr Psychol 1990; 15:659.",
"     </a>",
"    </li>",
"    <li>",
"     Croffie JMB, Fitzgerald JF. Idiopathic constipation. In: Pediatric Gastrointestinal Disease, 4th, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker Inc., Ontario 2004. p.1002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/106\">",
"      van der Plas RN, Benninga MA, Redekop WK, et al. Randomised trial of biofeedback training for encopresis. Arch Dis Child 1996; 75:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/107\">",
"      Voskuijl WP, Reitsma JB, van Ginkel R, et al. Longitudinal follow-up of children with functional nonretentive fecal incontinence. Clin Gastroenterol Hepatol 2006; 4:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/108\">",
"      De Caluw&eacute; D, Yoneda A, Akl U, Puri P. Internal anal sphincter achalasia: outcome after internal sphincter myectomy. J Pediatr Surg 2001; 36:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/109\">",
"      Irani K, Rodriguez L, Doody DP, Goldstein AM. Botulinum toxin for the treatment of chronic constipation in children with internal anal sphincter dysfunction. Pediatr Surg Int 2008; 24:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/110\">",
"      Keshtgar AS, Ward HC, Sanei A, Clayden GS. Botulinum toxin, a new treatment modality for chronic idiopathic constipation in children: long-term follow-up of a double-blind randomized trial. J Pediatr Surg 2007; 42:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/111\">",
"      Christison-Lagay ER, Rodriguez L, Kurtz M, et al. Antegrade colonic enemas and intestinal diversion are highly effective in the management of children with intractable constipation. J Pediatr Surg 2010; 45:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/112\">",
"      Wong AL, Kravarusic D, Wong SL. Impact of cecostomy and antegrade colonic enemas on management of fecal incontinence and constipation: ten years of experience in pediatric population. J Pediatr Surg 2008; 43:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/113\">",
"      Siddiqui AA, Fishman SJ, Bauer SB, Nurko S. Long-term follow-up of patients after antegrade continence enema procedure. J Pediatr Gastroenterol Nutr 2011; 52:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/114\">",
"      Mugie SM, Machado RS, Mousa HM, et al. Ten-year experience using antegrade enemas in children. J Pediatr 2012; 161:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/115\">",
"      Villarreal J, Sood M, Zangen T, et al. Colonic diversion for intractable constipation in children: colonic manometry helps guide clinical decisions. J Pediatr Gastroenterol Nutr 2001; 33:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/116\">",
"      Levitt MA, Pe&ntilde;a A. Surgery and constipation: when, how, yes, or no? J Pediatr Gastroenterol Nutr 2005; 41 Suppl 1:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/117\">",
"      Asipu D, Jaffray B. Treatment of severe childhood constipation with restorative proctocolectomy. Arch Dis Child 2010; 95:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/118\">",
"      Keuzenkamp-Jansen CW, Fijnvandraat CJ, Kneepkens CM, Douwes AC. Diagnostic dilemmas and results of treatment for chronic constipation. Arch Dis Child 1996; 75:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/119\">",
"      Abrahamian FP, Lloyd-Still JD. Chronic constipation in childhood: a longitudinal study of 186 patients. J Pediatr Gastroenterol Nutr 1984; 3:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/120\">",
"      Sutphen JL, Borowitz SM, Hutchison RL, Cox DJ. Long-term follow-up of medically treated childhood constipation. Clin Pediatr (Phila) 1995; 34:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/121\">",
"      Pijpers MA, Bongers ME, Benninga MA, Berger MY. Functional constipation in children: a systematic review on prognosis and predictive factors. J Pediatr Gastroenterol Nutr 2010; 50:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/122\">",
"      Loening-Baucke V. Factors determining outcome in children with chronic constipation and faecal soiling. Gut 1989; 30:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/123\">",
"      Loening-Baucke V. Prevalence, symptoms and outcome of constipation in infants and toddlers. J Pediatr 2005; 146:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/28/36298/abstract/124\">",
"      Bongers ME, van Wijk MP, Reitsma JB, Benninga MA. Long-term prognosis for childhood constipation: clinical outcomes in adulthood. Pediatrics 2010; 126:e156.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5873 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36298=[""].join("\n");
var outline_f35_28_36298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT OF INFANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT OF CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Education",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - School issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Bowel retraining",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Disimpaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10191107\">",
"      Oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10191116\">",
"      Rectal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10191125\">",
"      Oral and rectal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3942228\">",
"      - Maintenance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Laxatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10191134\">",
"      Polyethylene glycol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10191176\">",
"      Mineral oil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10191197\">",
"      Milk of magnesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10191204\">",
"      Lactulose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10191211\">",
"      Stimulant laxatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3942235\">",
"      Newer pharmacological agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Behavior modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dietary changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Fiber",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fluid intake",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1989137\">",
"      - Cow's milk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3942250\">",
"      - Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DISCONTINUATION OF LAXATIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT OF NONRETENTIVE FECAL INCONTINENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Anal sphincter release",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Non-retentive fecal incontinence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5873\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5873|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/2/15397\" title=\"figure 1\">",
"      Encopresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/2/9249\" title=\"figure 2A\">",
"      Stool diary sample",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/25/38303\" title=\"figure 2B\">",
"      Stool diary blank",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5873|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/14/23788\" title=\"table 1\">",
"      Rome III constipation child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/43/34491\" title=\"table 2\">",
"      Medical treatment of chronic constipation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/50/813\" title=\"table 3\">",
"      Encopresis treatment plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/56/6029\" title=\"table 4\">",
"      Laxatives for children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/8/26763\" title=\"table 5\">",
"      OTC fiber supplements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=related_link\">",
"      Constipation in children: Etiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/9/44182?source=related_link\">",
"      Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26344?source=related_link\">",
"      Overview of the management of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/2/43041?source=related_link\">",
"      Patient information: Constipation in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/7/15477?source=related_link\">",
"      Patient information: Constipation in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/59/27570?source=related_link\">",
"      Patient information: Fecal incontinence in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2710?source=related_link\">",
"      Prevention and treatment of acute constipation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_28_36299="Abnormal findings on a modified barium swallow";
var content_f35_28_36299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Abnormal radiographic findings on a modified barium swallow",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Phase",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiographic finding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Oral preparatory",
"        </strong>",
"       </td>",
"       <td>",
"        Lack of bolus formation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adherence to hard palate",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Oral",
"        </strong>",
"       </td>",
"       <td>",
"        Delayed oral transit time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduced tongue elevation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tongue incoordination",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        <strong>",
"         Pharyngeal",
"        </strong>",
"       </td>",
"       <td>",
"        Velopharyngeal incoordination/reflux",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delayed pharyngeal transit time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pooling in pharyngeal recesses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Residue in pharyngeal recesses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngeal penetration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cricopharyngeal dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspiration",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Esophageal",
"        </strong>",
"       </td>",
"       <td>",
"        Reduced esophageal peristalsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastroesophageal reflux",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36299=[""].join("\n");
var outline_f35_28_36299=null;
var title_f35_28_36300="Irradiance formula";
var content_f35_28_36300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Irradiance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 188px; background-image: url(data:image/gif;base64,R0lGODlhzwG8AMQAAP///wAAACIiIoiIiGZmZkRERJmZmd3d3TMzM8zMzO7u7ru7uxEREVVVVXd3d6qqqkBAQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADPAbwAAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKFBQKKAgU1BAF+DAgjAwEDIwwNKbgjBgELs1u1t7k0u34OAQoiDQHGAAnCx9EAyszNWc8lBQHpCAkiCQjpDMMAC+8IByIHwui2JPkE7wEcJBOQrsG1YOwUBMT2a169ewDyDdhnwp06dgDMAZiGLl0AA8ocMAjAwIAIjdOC/3kksOdBgAciGAhgIALhAYABClzrmE6ZR1sGCAZAMI6cE40jBJhUIIAfMgADjHUbpgCBwHwCivYbykyZyQXeEiCbGi6AU4Fkq141q3WEAga5qjLYyW8jLwBPyxa4t+seyrvT+igU6FIZuwY06bHrxhIvOHH4vCkgIM9oE6Qmgh0YXKIBOJcJ8pk8IZqYsQZ1EQJgwLLBuwQKYXoeAbr0Cc3tvP0VkVcZRLK77f5B8MsBAoXDipkw13uZCJcwLUfBHC6bx3vZBFDm7dHjAtsmwD8TsG3eRwCuVz8Q4MDlNaHdv58/QYDmiAAsgzeHCAB/xrqBBdZHNWqh1wBZUOHk1P9jzgHA1FAEtCVdEpgpcyBUAUBkwD854VXeCOCVIN4v5I0AlknBGDCXccbx9mFko5lQHwn+6ccgfwsFJyAfhb0EVTzW2EUAXbwxqNUABBBU2YQU1iXCjDVlWEI1ByAW3nxXxsgaeqkFsJhZxoDFHjb2bRVjCbhx4w2UwjmWjJRqmsRmgHf1QtA13QjQUIknLfimhAAg4CSTR2CmGj0Z3jSaoGrq5NABIW7VWF/msSQWOCONNlJ03ThKD6RYlvDWcXId5OMAI5F5TVlLMYohTKjeFQygeGTT0GoL/XeQTKrmJo8BFx6wJaEUdmeWAh0hkM1mu1wkAqLpDBkpiEOlk9X/QAWtil6QABBoIk7ShlqCRUNhlFE6BaDTDkAgVTsUfx2lexey0fYRjEDY+MgNQK7xQ65J1ZiVAE8GETvHtF74ZvDCaiDchcIMR1yGw1xALPHFGGes8cYcd+xxG816h6GxDqyqUnclk6BQOkvyVFB0ZXVX2creAAPPqrvUpcDJATHjcr0fB20D0CPf002HRauJdJTqkEARAA+M1LJZaHp068jaPEl1RAQ5qswwTwst9tD+MQ1RR2aflA4JOHk5Qtg+wRy2CG2byzNMOas9l4lgbz323zIQrRJE9aQd6FAjHO0Tvuc6OVJ5cyueDuMqESTAZFQfzbjTfqfws7WAu8Fz/3f8xSF4Ovf4NM7gMRe1y1zZlDm35W93/roCsdu8TLR5g1XzOcaKG/rwNJaNtUd2B2/uW/65pO/sfofNPEvOR6eSXWZR7fuStQ9KdvDghy/++OSXb/756Kev/vrst+/++RAg8f778d9weobOlzd4/m8GH83cj+te/4wVjes9CHSaO8Hc7De/BjrwgRCMoAQnyL76GYGC5rNgDe53j4DJg3Ue1NsIrOMXv6lOgCLMl5SuB7Wf6E1bCeib95YDvhkSjwyjuw4dOOggobCDdQcMzeRow7LGPUdqnONHPnLVQm+wcFtbS8BIHBU1Gd7wijIyFjNYpzQBHICLRxOASsyFK/9b/KwBRfGJRwYwRhKMxBZPFJbfdiYzdnyuMVjMox73yMc++vGPgAykIAdJSEIOQCh4LOQIkvQKRjbCP2Dh3oSMVwRHQuNPO7DkIsqjnYVRkgiaRERefBBKRkjEk4mMCE4chbW91CSAIvDKO1KZpGatY5FFxMcqr5GPAgCEjUI5EwmgRRSJUIRct9wXPKhinU9iiyvPegiIOhIPl7VrHEHJlouscxy1OWsjMzxZSZ4kxkz9KGu1+yYVQsYSZdSHJAsImADIqCtUlkAxamqncwa2RQYwwx0mUYY96OOfqvDDNam7JT4ZExG2dAuau9BW4spGGayM4y1xQcDenhIVcCb/lDSS2U5arNLDbna0OcyIJDeeoiQ14UspPeRHKTMij2XZRX/+3NdoYMoUGzYBMeygR1kG+g5X6okEDSBA6QjlTKfZwlturIxIyrLURXYpAd0oirKWYwvbnOg5DUJqmWBks98IgzNsu9oJoNOZz3hJNSRAKZdsxo5O0g0cZQXnCr6qyXiMYKpVq2oTEPQmiKSpGm8TLJOcOQAFKS2p91iisaiKAkueSI0eKaBjvTofsEiIT9SKEZv60xqzbGdkBMAXZjdDEAREiDtaHG2RMAnar9o1I9EAFun0WpGQnceSku1OLJsJpygYpgQQS1MwHIQASRLrk7sY0n9EMJlmyUeS/xYrgWVfclzt4odInB2NZ00AWrI+aaxl21BR20GA2EmUBEhqaXnPS14jechE57ltuspyIdyUMh8I+Mpv63JK5Grjh8WFQncLGyXD8sJ3wjXYJ0GLGYWwRDkGVqwlNUPYpECuq50NsYSsZKa8qol7VCJBYVbAKBLD121xtS9q6IoXPO6XTf71Xnf56rgXbaRMaYpChymLIQdv7JO12JUtCCDdFd+rJrnILgnqs5hhIWY0DsjP5X4EYvGK2AQumdQAwDMqBZRKUXQzozxSjNxgbalT1/iUsEx6mr2VJaX+uRRvbJyLQ72DL95T6QHQIScnPRkqfXYbohTLBEEF9RfJhf/TcjUWPAKQq1/hwEllDmmtYUh5kb4oCAkCNhSTXJpR4X1WWEmQTa6ECJkJCdktY2UWYbaDYKuC1neVSZJh/Asy4RBKwWr8trgky6YzlecuCo0moYjRQcdOMBRwtxIiK7dOisy2trfN7W57+9vgDre4x03ucpv73OhOt7rXze52u/vd8I63vOdN73rb+974zre+983vfvv73wAPuMAHTvCCG/zgCE+4whfO8IY7/OEQj7jEJ07xilv84hjPuMY3zvGOe/zjIA+5yEdO8pKb/OQoT7nKV87ylrv85TCPucxnTvOa2/zmOK/DbXPeCgg7lwU753krChyDoAt9FQWGdZ//cLlnfOyjKOTy69E9cUqMMndv+mEJU6JBAEdx1MdTx8Qp0wQcAN2lk6haFXLQGvZPnHK0NTJ7031bxOyctu2beDt6tcx0Yss2GRzCK94vQRayr6lMgUE7jFHA5sFfohrMKHOpXnXOpjPlllUyAJoD5VPHN6JZUud1Ms+VE3UROyLNPBDm1On51rv+9bCPvexnT/vaJ2EkDVnZrWBJN1EzLXg59MizmumAMdv+D9a5hvOkdLTKHC0d7/Wdred2QszR6vh2cB47SD2MNoqA1L9TtfDmtt5kXB/7dFjZMN4RwOy4MSCFG2ZPaOgkgsTj/BA2lq3Rf4Z3GKQnJIErjKM6/94nftPXOaODADDDf3pQDUByHACoL0a0MpsjffSHXG0jgTOAQeijQQwYA85DEAJRD9AXGcFjZ+Yxfp0zTAGTSjHAgfDzgTTAPOkAK1ajOxihEjFigcDjJII3RPcUPvsng2NgHfbxfJXRWm6BLvilgk5Sa1HCAIxGhHCgEuUxEjC2PUiFOgZ4gXwDH8ZHhWI4hmRYhmZ4hmiYhmq4hmzYhm74hnD4gdQGNIPmULhENHFICEnyUVv3JI4CVA6Rh4ZAHGhiZ8gxZIJICCqRWlpjLAOwYIloCAnQXiQxGWMVS4sXiYhQGHA1UT+niX5QAGuWIZfHDpnHeY8GioFAazCFejwecSFz2FSqOIu0WIu2eIu4mIu6uIu82Iu++IvAGIzCOIzEWIzGeIzImIzKuIzM2IzO+IzQGI3SOI1wEAIAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36300=[""].join("\n");
var outline_f35_28_36300=null;
var title_f35_28_36301="Diaphragm";
var content_f35_28_36301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diaphragm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36301=[""].join("\n");
var outline_f35_28_36301=null;
var title_f35_28_36302="Evaluation vent tachycardia";
var content_f35_28_36302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Diagnostic evaluation in children with ventricular tachycardia (VT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 234px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ARVD: arrhythmic right ventricular dysplasia; CHD: congenital heart disease; HCM: hypertrophic cardiomyopathy; LBBB: left bundle branch block; LQTS: long QT syndrome; RBBB: right bundle branch block.",
"     <br>",
"      * Family history may be important.",
"      <br>",
"       &bull; Echocardiogram may be normal.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36302=[""].join("\n");
var outline_f35_28_36302=null;
var title_f35_28_36303="Vertical band gastroplasty";
var content_f35_28_36303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vertical band gastroplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vertical banded gastroplasty is a purely restrictive procedure in which the upper part of the stomach is partitioned by a vertical staple line with a tight outlet wrapped by a prosthetic mesh or band. The small upper stomach pouch gets filled quickly by solid food and prevents consumption of a large meal. Weight loss occurs because of decreased caloric intake of solid food.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &copy; 2010 Cine-Med.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_28_36303=[""].join("\n");
var outline_f35_28_36303=null;
